메뉴 건너뛰기




Volumn 67, Issue 4, 2018, Pages 1560-1599

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; CYTOTOXIC AGENT; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; TELBIVUDINE; TENOFOVIR; TENOFOVIR ALAFENAMIDE; TENOFOVIR DIPOVOXIL FUMARATE; UNCLASSIFIED DRUG; VIRUS DNA; ANTIVIRUS AGENT;

EID: 85044252801     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.29800     Document Type: Article
Times cited : (3026)

References (273)
  • 2
    • 84951792292 scopus 로고    scopus 로고
    • Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis
    • Lok AS, McMahon BJ, Brown RS, Jr., Wong JB, Ahmed AT, Farah W, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis. Hepatology 2016;63:284-306.
    • (2016) Hepatology , vol.63 , pp. 284-306
    • Lok, A.S.1    McMahon, B.J.2    Brown, R.S.3    Wong, J.B.4    Ahmed, A.T.5    Farah, W.6
  • 3
    • 84951795052 scopus 로고    scopus 로고
    • Antiviral therapy in management of chronic hepatitis B viral infection in children: a systematic review and meta-analysis
    • Jonas MM, Lok AS, McMahon BJ, Brown RS, Jr., Wong JB, Ahmed AT, et al. Antiviral therapy in management of chronic hepatitis B viral infection in children: a systematic review and meta-analysis. Hepatology 2016;63:307-318.
    • (2016) Hepatology , vol.63 , pp. 307-318
    • Jonas, M.M.1    Lok, A.S.2    McMahon, B.J.3    Brown, R.S.4    Wong, J.B.5    Ahmed, A.T.6
  • 4
    • 84951761513 scopus 로고    scopus 로고
    • Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis
    • Brown RS, Jr., McMahon BJ, Lok AS, Wong JB, Ahmed AT, Mouchli MA, et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis. Hepatology 2016;63:319-333.
    • (2016) Hepatology , vol.63 , pp. 319-333
    • Brown, R.S.1    McMahon, B.J.2    Lok, A.S.3    Wong, J.B.4    Ahmed, A.T.5    Mouchli, M.A.6
  • 6
    • 85019805535 scopus 로고    scopus 로고
    • A phase 3 study comparing tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) in patients with HBeAg-positive, chronic hepatitis B: efficacy and safety results at week 96
    • Agarwal K, Fung S, Seto WK, Lim Y, Gane E, Janssen H, et al. A phase 3 study comparing tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) in patients with HBeAg-positive, chronic hepatitis B: efficacy and safety results at week 96. J Hepatol 2017;66(Suppl 1):S478.
    • (2017) J Hepatol , vol.66 , pp. S478
    • Agarwal, K.1    Fung, S.2    Seto, W.K.3    Lim, Y.4    Gane, E.5    Janssen, H.6
  • 7
    • 85019798687 scopus 로고    scopus 로고
    • A Phase 3 Study Comparing Tenofovir Alafenamide (TAF) to Tenofovir Disoproxil Fumarate (TDF) in Patients With HBeAg-Negative, Chronic Hepatitis B (CHB): Efficacy and Safety Results at Week 96
    • Brunetto M, Lim YS, Gane E, Seto WK, Osipenko M, Ahn SH, et al. A Phase 3 Study Comparing Tenofovir Alafenamide (TAF) to Tenofovir Disoproxil Fumarate (TDF) in Patients With HBeAg-Negative, Chronic Hepatitis B (CHB): Efficacy and Safety Results at Week 96. J Hepatol 2017;152(Suppl 1):S1086.
    • (2017) J Hepatol , vol.152 , pp. S1086
    • Brunetto, M.1    Lim, Y.S.2    Gane, E.3    Seto, W.K.4    Osipenko, M.5    Ahn, S.H.6
  • 8
    • 78650477355 scopus 로고    scopus 로고
    • Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B
    • Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011;140:132-143.
    • (2011) Gastroenterology , vol.140 , pp. 132-143
    • Heathcote, E.J.1    Marcellin, P.2    Buti, M.3    Gane, E.4    De Man, R.A.5    Krastev, Z.6
  • 9
    • 21244447705 scopus 로고    scopus 로고
    • Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
    • Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352:2682-2695.
    • (2005) N Engl J Med. , vol.352 , pp. 2682-2695
    • Lau, G.K.1    Piratvisuth, T.2    Luo, K.X.3    Marcellin, P.4    Thongsawat, S.5    Cooksley, G.6
  • 10
    • 80055059164 scopus 로고    scopus 로고
    • Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C
    • Liaw YF, Jia JD, Chan HL, Han KH, Tanwandee T, Chuang WL, et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology 2011;54:1591-1599.
    • (2011) Hepatology , vol.54 , pp. 1591-1599
    • Liaw, Y.F.1    Jia, J.D.2    Chan, H.L.3    Han, K.H.4    Tanwandee, T.5    Chuang, W.L.6
  • 11
    • 19944428132 scopus 로고    scopus 로고
    • Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial
    • Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365:123-129.
    • (2005) Lancet , vol.365 , pp. 123-129
    • Janssen, H.L.1    van Zonneveld, M.2    Senturk, H.3    Zeuzem, S.4    Akarca, U.S.5    Cakaloglu, Y.6
  • 12
    • 48549107919 scopus 로고    scopus 로고
    • Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b
    • Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008;135:459-467.
    • (2008) Gastroenterology , vol.135 , pp. 459-467
    • Buster, E.H.1    Flink, H.J.2    Cakaloglu, Y.3    Simon, K.4    Trojan, J.5    Tabak, F.6
  • 13
    • 84865490229 scopus 로고    scopus 로고
    • Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B
    • Lok AS, Trinh H, Carosi G, Akarca US, Gadano A, Habersetzer F, et al. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. Gastroenterology 2012;143:619-628.e1.
    • (2012) Gastroenterology , vol.143 , pp. 619-628.e1
    • Lok, A.S.1    Trinh, H.2    Carosi, G.3    Akarca, U.S.4    Gadano, A.5    Habersetzer, F.6
  • 14
    • 35649020315 scopus 로고    scopus 로고
    • Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B
    • Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007;133:1437-1444.
    • (2007) Gastroenterology , vol.133 , pp. 1437-1444
    • Gish, R.G.1    Lok, A.S.2    Chang, T.T.3    de Man, R.A.4    Gadano, A.5    Sollano, J.6
  • 15
    • 57349095400 scopus 로고    scopus 로고
    • Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B
    • Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-2455.
    • (2008) N Engl J Med , vol.359 , pp. 2442-2455
    • Marcellin, P.1    Heathcote, E.J.2    Buti, M.3    Gane, E.4    de Man, R.A.5    Krastev, Z.6
  • 16
    • 33644822860 scopus 로고    scopus 로고
    • Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B
    • Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-1020.
    • (2006) N Engl J Med , vol.354 , pp. 1011-1020
    • Lai, C.L.1    Shouval, D.2    Lok, A.S.3    Chang, T.T.4    Cheinquer, H.5    Goodman, Z.6
  • 17
    • 84996520524 scopus 로고    scopus 로고
    • Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial
    • Chan HL, Fung S, Seto WK, Chuang WL, Chen CY, Kim HJ, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 2016;1:185-195.
    • (2016) Lancet Gastroenterol Hepatol , vol.1 , pp. 185-195
    • Chan, H.L.1    Fung, S.2    Seto, W.K.3    Chuang, W.L.4    Chen, C.Y.5    Kim, H.J.6
  • 18
    • 84996538096 scopus 로고    scopus 로고
    • Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial
    • Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 2016;1:196-206.
    • (2016) Lancet Gastroenterol Hepatol , vol.1 , pp. 196-206
    • Buti, M.1    Gane, E.2    Seto, W.K.3    Chan, H.L.4    Chuang, W.L.5    Stepanova, T.6
  • 19
    • 85014799936 scopus 로고    scopus 로고
    • Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results
    • Arribas JR, Thompson M, Sax PE, Haas B, McDonald C, Wohl DA, et al. Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results. J Acquir Immune Defic Syndr 2017;75:211-218.
    • (2017) J Acquir Immune Defic Syndr , vol.75 , pp. 211-218
    • Arribas, J.R.1    Thompson, M.2    Sax, P.E.3    Haas, B.4    McDonald, C.5    Wohl, D.A.6
  • 20
    • 85014657477 scopus 로고    scopus 로고
    • Brief Report: Long-term (96-week) Efficacy and Safety After Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) in HIV-infected, Virologically Suppressed Adults
    • Raffi F, Orkin C, Clarke A, Slama L, Gallant J, Daar E, et al. Brief Report: Long-term (96-week) Efficacy and Safety After Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) in HIV-infected, Virologically Suppressed Adults. J Acquir Immune Defic Syndr 2017;75:226-231.
    • (2017) J Acquir Immune Defic Syndr , vol.75 , pp. 226-231
    • Raffi, F.1    Orkin, C.2    Clarke, A.3    Slama, L.4    Gallant, J.5    Daar, E.6
  • 21
    • 1642410856 scopus 로고    scopus 로고
    • Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures
    • Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97-107.
    • (2004) J Viral Hepat , vol.11 , pp. 97-107
    • Lavanchy, D.1
  • 22
    • 84992187280 scopus 로고    scopus 로고
    • Epidemiology of Hepatitis B Virus Infection and Impact of Vaccination on Disease
    • Nelson NP, Easterbrook PJ, McMahon BJ. Epidemiology of Hepatitis B Virus Infection and Impact of Vaccination on Disease. Clin Liver Dis 2016;20:607-628.
    • (2016) Clin Liver Dis , vol.20 , pp. 607-628
    • Nelson, N.P.1    Easterbrook, P.J.2    McMahon, B.J.3
  • 23
    • 52649120886 scopus 로고    scopus 로고
    • Recommendations for identification and public health management of persons with chronic hepatitis B virus infection
    • Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008;57:1-20.
    • (2008) MMWR Recomm Rep , vol.57 , pp. 1-20
    • Weinbaum, C.M.1    Williams, I.2    Mast, E.E.3    Wang, S.A.4    Finelli, L.5    Wasley, A.6
  • 24
    • 33644698390 scopus 로고    scopus 로고
    • A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents
    • Mast EE, Margolis HS, Fiore AE, Brink EW, Goldstein ST, Wang SA, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005;54:1-31.
    • (2005) MMWR Recomm Rep , vol.54 , pp. 1-31
    • Mast, E.E.1    Margolis, H.S.2    Fiore, A.E.3    Brink, E.W.4    Goldstein, S.T.5    Wang, S.A.6
  • 26
    • 84916910477 scopus 로고    scopus 로고
    • Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype
    • Ghany MG, Perrillo R, Li R, Belle SH, Janssen HL, Terrault NA, et al. Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype. Clin Gastroenterol Hepatol 2015;13:183-192.
    • (2015) Clin Gastroenterol Hepatol , vol.13 , pp. 183-192
    • Ghany, M.G.1    Perrillo, R.2    Li, R.3    Belle, S.H.4    Janssen, H.L.5    Terrault, N.A.6
  • 29
    • 0020682268 scopus 로고
    • Postnatal infectivity of hepatitis B surface antigen-carrier mothers
    • Beasley RP, Huang LY. Postnatal infectivity of hepatitis B surface antigen-carrier mothers. J Infect Dis 1983;147:185-190.
    • (1983) J Infect Dis , vol.147 , pp. 185-190
    • Beasley, R.P.1    Huang, L.Y.2
  • 31
    • 0023228823 scopus 로고
    • Age- and sex-related study of hepatitis B virus chronic carrier state in infants from an endemic area (Senegal)
    • Coursaget P, Yvonnet B, Chotard J, Vincelot P, Sarr M, Diouf C, Chiron JP, et al. Age- and sex-related study of hepatitis B virus chronic carrier state in infants from an endemic area (Senegal). J Med Virol 1987;22:1-5.
    • (1987) J Med Virol , vol.22 , pp. 1-5
    • Coursaget, P.1    Yvonnet, B.2    Chotard, J.3    Vincelot, P.4    Sarr, M.5    Diouf, C.6    Chiron, J.P.7
  • 32
    • 0022000510 scopus 로고
    • Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state
    • McMahon BJ, Alward WL, Hall DB, Heyward WL, Bender TR, Francis DP, Maynard JE. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985;151:599-603.
    • (1985) J Infect Dis , vol.151 , pp. 599-603
    • McMahon, B.J.1    Alward, W.L.2    Hall, D.B.3    Heyward, W.L.4    Bender, T.R.5    Francis, D.P.6    Maynard, J.E.7
  • 34
    • 0025779460 scopus 로고
    • The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state
    • Bodsworth N, Cooper D, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 1991;163:1138-1140.
    • (1991) J Infect Dis , vol.163 , pp. 1138-1140
    • Bodsworth, N.1    Cooper, D.2    Donovan, B.3
  • 35
    • 84255162321 scopus 로고    scopus 로고
    • Use of hepatitis B vaccination for adults with diabetes mellitus recommendations of the Advisory Committee on Immunization Practices (ACIP)
    • Centers for Disease Control and Prevention. Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2011;60:1709-1711.
    • (2011) MMWR Morb Mortal Wkly Rep , vol.60 , pp. 1709-1711
  • 38
    • 70349240414 scopus 로고    scopus 로고
    • Chronic hepatitis B: update 2009
    • Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-662.
    • (2009) Hepatology , vol.50 , pp. 661-662
    • Lok, A.S.1    McMahon, B.J.2
  • 39
    • 84981167133 scopus 로고    scopus 로고
    • Letter: hepatitis B surface seroclearance does reduce the risk of hepatocellular carcinoma—authors’ reply
    • Gounder PP, Bulkow LR, McMahon BJ. Letter: hepatitis B surface seroclearance does reduce the risk of hepatocellular carcinoma—authors’ reply. Aliment Pharmacol Ther 2016;44:650-651.
    • (2016) Aliment Pharmacol Ther , vol.44 , pp. 650-651
    • Gounder, P.P.1    Bulkow, L.R.2    McMahon, B.J.3
  • 40
    • 84908555338 scopus 로고    scopus 로고
    • Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma
    • Liu J, Yang HI, Lee MH, Lu SN, Jen CL, Batrla-Utermann R, et al. Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma. Gut 2014;63:1648-1657.
    • (2014) Gut , vol.63 , pp. 1648-1657
    • Liu, J.1    Yang, H.I.2    Lee, M.H.3    Lu, S.N.4    Jen, C.L.5    Batrla-Utermann, R.6
  • 41
    • 84978976118 scopus 로고    scopus 로고
    • Hepatitis B surface antigen loss: not all that we hoped it would be
    • Nathanson MH, Terrault N. Hepatitis B surface antigen loss: not all that we hoped it would be. Hepatology 2016;64:328-329.
    • (2016) Hepatology , vol.64 , pp. 328-329
    • Nathanson, M.H.1    Terrault, N.2
  • 42
    • 0344393499 scopus 로고    scopus 로고
    • Low prevalence of ongoing hepatitis B viremia in HIV-positive individuals with isolated antibody to hepatitis B core antigen
    • Gandhi RT, Wurcel A, McGovern B, Lee H, Shopis J, Corcoran CP, et al. Low prevalence of ongoing hepatitis B viremia in HIV-positive individuals with isolated antibody to hepatitis B core antigen. J Acquir Immune Defic Syndr 2003;34:439-441.
    • (2003) J Acquir Immune Defic Syndr , vol.34 , pp. 439-441
    • Gandhi, R.T.1    Wurcel, A.2    McGovern, B.3    Lee, H.4    Shopis, J.5    Corcoran, C.P.6
  • 43
    • 34248355202 scopus 로고    scopus 로고
    • Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study
    • Ikeda K, Marusawa H, Osaki Y, Nakamura T, Kitajima N, Yamashita Y, et al. Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study. Ann Intern Med 2007;146:649-656.
    • (2007) Ann Intern Med , vol.146 , pp. 649-656
    • Ikeda, K.1    Marusawa, H.2    Osaki, Y.3    Nakamura, T.4    Kitajima, N.5    Yamashita, Y.6
  • 44
    • 0023676508 scopus 로고
    • Prevalence of isolated antibody to hepatitis B core antigen in an area endemic for hepatitis B virus infection: implications in hepatitis B vaccination programs
    • Lok AS, Lai CL, Wu PC. Prevalence of isolated antibody to hepatitis B core antigen in an area endemic for hepatitis B virus infection: implications in hepatitis B vaccination programs. Hepatology 1988;8:766-770.
    • (1988) Hepatology , vol.8 , pp. 766-770
    • Lok, A.S.1    Lai, C.L.2    Wu, P.C.3
  • 48
    • 85021228368 scopus 로고    scopus 로고
    • Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: a meta-analysis
    • Paul S, Dickstein A, Saxena A, Terrin N, Viveiros K, Balk EM, Wong JB. Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: a meta-analysis. Hepatology 2017;66:379-388.
    • (2017) Hepatology , vol.66 , pp. 379-388
    • Paul, S.1    Dickstein, A.2    Saxena, A.3    Terrin, N.4    Viveiros, K.5    Balk, E.M.6    Wong, J.B.7
  • 49
    • 0023759015 scopus 로고
    • Long-term follow-up in a randomised controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection
    • Lok AS, Lai CL, Wu PC, Leung EK. Long-term follow-up in a randomised controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection. Lancet 1988;2:298-302.
    • (1988) Lancet , pp. 2:298-302
    • Lok, A.S.1    Lai, C.L.2    Wu, P.C.3    Leung, E.K.4
  • 50
    • 17644391701 scopus 로고    scopus 로고
    • Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies
    • Gandhi RT, Wurcel A, Lee H, McGovern B, Shopis J, Geary M, et al. Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. J Infect Dis 2005;191:1435-1441.
    • (2005) J Infect Dis , vol.191 , pp. 1435-1441
    • Gandhi, R.T.1    Wurcel, A.2    Lee, H.3    McGovern, B.4    Shopis, J.5    Geary, M.6
  • 51
    • 84966704136 scopus 로고    scopus 로고
    • Vaccination Against Hepatitis B Virus (HBV) in HIV-1-Infected Patients With Isolated Anti-HBV Core Antibody: The ANRS HB EP03 CISOVAC Prospective Study
    • Piroth L, Launay O, Michel ML, Bourredjem A, Miailhes P, Ajana F, et al. Vaccination Against Hepatitis B Virus (HBV) in HIV-1-Infected Patients With Isolated Anti-HBV Core Antibody: The ANRS HB EP03 CISOVAC Prospective Study. J Infect Dis 2016;213:1735-1742.
    • (2016) J Infect Dis , vol.213 , pp. 1735-1742
    • Piroth, L.1    Launay, O.2    Michel, M.L.3    Bourredjem, A.4    Miailhes, P.5    Ajana, F.6
  • 52
    • 53749089012 scopus 로고    scopus 로고
    • HB vaccination in the prevention of viral reactivation in allogeneic hematopoietic stem cell transplantation recipients with previous HBV infection
    • Onozawa M, Hashino S, Darmanin S, Okada K, Morita R, Takahata M, et al. HB vaccination in the prevention of viral reactivation in allogeneic hematopoietic stem cell transplantation recipients with previous HBV infection. Biol Blood Marrow Transplant 2008;14:1226-1230.
    • (2008) Biol Blood Marrow Transplant , vol.14 , pp. 1226-1230
    • Onozawa, M.1    Hashino, S.2    Darmanin, S.3    Okada, K.4    Morita, R.5    Takahata, M.6
  • 53
    • 84907934932 scopus 로고    scopus 로고
    • Hepatitis B virus (HBV) reverse seroconversion (RS) can be prevented even in non-responders to hepatitis B vaccine after allogeneic stem cell transplantation: long-term analysis of intervention in RS with vaccine for patients with previous HBV infection
    • Takahata M, Hashino S, Onozawa M, Shigematsu A, Sugita J, Fujimoto K, et al. Hepatitis B virus (HBV) reverse seroconversion (RS) can be prevented even in non-responders to hepatitis B vaccine after allogeneic stem cell transplantation: long-term analysis of intervention in RS with vaccine for patients with previous HBV infection. Transplant Infect Dis 2014;16:797-801.
    • (2014) Transplant Infect Dis , vol.16 , pp. 797-801
    • Takahata, M.1    Hashino, S.2    Onozawa, M.3    Shigematsu, A.4    Sugita, J.5    Fujimoto, K.6
  • 54
    • 84896400692 scopus 로고    scopus 로고
    • Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B—a prospective cohort study with paired transient elastography examinations
    • Wong GL, Chan HL, Yu Z, Chan AW, Choi PC, Chim AM, Chan HY, et al. Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B—a prospective cohort study with paired transient elastography examinations. Aliment Pharmacol Ther 2014;39:883-893.
    • (2014) Aliment Pharmacol Ther , vol.39 , pp. 883-893
    • Wong, G.L.1    Chan, H.L.2    Yu, Z.3    Chan, A.W.4    Choi, P.C.5    Chim, A.M.6    Chan, H.Y.7
  • 55
    • 85015818476 scopus 로고    scopus 로고
    • Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B
    • Chan AW, Wong GL, Chan HY, Tong JH, Yu YH, Choi PC, et al. Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. J Gastroenterol Hepatol 2017;32:667-676.
    • (2017) J Gastroenterol Hepatol , vol.32 , pp. 667-676
    • Chan, A.W.1    Wong, G.L.2    Chan, H.Y.3    Tong, J.H.4    Yu, Y.H.5    Choi, P.C.6
  • 56
    • 0020370413 scopus 로고
    • Susceptibility of chronic symptomless HBsAg carriers to ethanol-induced hepatic damage
    • Villa E, Rubbiani L, Barchi T, Ferretti I, Grisendi A, De Palma M, et al. Susceptibility of chronic symptomless HBsAg carriers to ethanol-induced hepatic damage. Lancet 1982;2(8310):1243-1244.
    • (1982) Lancet , vol.2 , Issue.8310 , pp. 1243-1244
    • Villa, E.1    Rubbiani, L.2    Barchi, T.3    Ferretti, I.4    Grisendi, A.5    De Palma, M.6
  • 58
    • 0026735233 scopus 로고
    • Hepatitis B virus, cigarette smoking and alcohol consumption in the development of hepatocellular carcinoma: a case-control study in Fukuoka, Japan
    • Tanaka K, Hirohata T, Takeshita S, Hirohata I, Koga S, Sugimachi K, et al. Hepatitis B virus, cigarette smoking and alcohol consumption in the development of hepatocellular carcinoma: a case-control study in Fukuoka, Japan. Int J Cancer 1992;51:509-514.
    • (1992) Int J Cancer , vol.51 , pp. 509-514
    • Tanaka, K.1    Hirohata, T.2    Takeshita, S.3    Hirohata, I.4    Koga, S.5    Sugimachi, K.6
  • 59
    • 0022649587 scopus 로고
    • A case-control study of hepatocellular carcinoma and the hepatitis B virus, cigarette smoking, and alcohol consumption
    • Austin H, Delzell E, Grufferman S, Levine R, Morrison AS, Stolley PD, Cole P. A case-control study of hepatocellular carcinoma and the hepatitis B virus, cigarette smoking, and alcohol consumption. Cancer Res 1986;46:962-966.
    • (1986) Cancer Res , vol.46 , pp. 962-966
    • Austin, H.1    Delzell, E.2    Grufferman, S.3    Levine, R.4    Morrison, A.S.5    Stolley, P.D.6    Cole, P.7
  • 60
    • 0020370413 scopus 로고
    • Susceptibility of chronic symptomless HBsAg carriers to ethanol-induced hepatic damage
    • Villa E, Rubbiani L, Barchi T, Ferretti I, Grisendi A, De Palma M, et al. Susceptibility of chronic symptomless HBsAg carriers to ethanol-induced hepatic damage. Lancet 1982;2:1243-1244.
    • (1982) Lancet , vol.2 , pp. 1243-1244
    • Villa, E.1    Rubbiani, L.2    Barchi, T.3    Ferretti, I.4    Grisendi, A.5    De Palma, M.6
  • 61
    • 33646715581 scopus 로고    scopus 로고
    • Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP)
    • Advisory Committee on Immunization P, Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55:1-23.
    • (2006) MMWR Recomm Rep , vol.55 , pp. 1-23
    • Fiore, A.E.1    Wasley, A.2    Bell, B.P.3
  • 62
    • 13344295086 scopus 로고    scopus 로고
    • Transmission of hepatitis B to multiple patients from a surgeon without evidence of inadequate infection control
    • Harpaz R, Seidlein LV, Averhoff FM, Tormey MP, Sinha SD, Kotsopoulou K, et al. Transmission of hepatitis B to multiple patients from a surgeon without evidence of inadequate infection control. N Engl J Med 1996;334:549-554.
    • (1996) N Engl J Med , vol.334 , pp. 549-554
    • Harpaz, R.1    Seidlein, L.V.2    Averhoff, F.M.3    Tormey, M.P.4    Sinha, S.D.5    Kotsopoulou, K.6
  • 63
    • 84865680485 scopus 로고    scopus 로고
    • Updated CDC recommendations for the management of hepatitis B virus-infected health-care providers and students
    • Centers for Disease Control and Prevention. Updated CDC recommendations for the management of hepatitis B virus-infected health-care providers and students. MMWR Recomm Rep 2012;61:1-12.
    • (2012) MMWR Recomm Rep , vol.61 , pp. 1-12
  • 64
    • 39049191182 scopus 로고    scopus 로고
    • A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults
    • quiz, CE31-CE34
    • Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006;55:1-33; quiz, CE31-CE34.
    • (2006) MMWR Recomm Rep , vol.55 , pp. 1-33
    • Mast, E.E.1    Weinbaum, C.M.2    Fiore, A.E.3    Alter, M.J.4    Bell, B.P.5    Finelli, L.6
  • 65
    • 84954075918 scopus 로고    scopus 로고
    • Clinical course of 161 untreated and tenofovir-treated chronic hepatitis B pregnant patients in a low hepatitis B virus endemic region
    • Samadi Kochaksaraei G, Castillo E, Osman M, Simmonds K, Scott AN, Oshiomogho JI, et al. Clinical course of 161 untreated and tenofovir-treated chronic hepatitis B pregnant patients in a low hepatitis B virus endemic region. J Viral Hepat 2016;23:15-22.
    • (2016) J Viral Hepat , vol.23 , pp. 15-22
    • Samadi Kochaksaraei, G.1    Castillo, E.2    Osman, M.3    Simmonds, K.4    Scott, A.N.5    Oshiomogho, J.I.6
  • 66
    • 84979497557 scopus 로고    scopus 로고
    • Serum Alanine Aminotransferase and Hepatitis B DNA Flares in Pregnant and Postpartum Women with Chronic Hepatitis B
    • Chang CY, Aziz N, Poongkunran M, Javaid A, Trinh HN, Lau D, Nguyen MH. Serum Alanine Aminotransferase and Hepatitis B DNA Flares in Pregnant and Postpartum Women with Chronic Hepatitis B. Am J Gastroenterol 2016;111:1410-1415.
    • (2016) Am J Gastroenterol , vol.111 , pp. 1410-1415
    • Chang, C.Y.1    Aziz, N.2    Poongkunran, M.3    Javaid, A.4    Trinh, H.N.5    Lau, D.6    Nguyen, M.H.7
  • 67
    • 85015744335 scopus 로고    scopus 로고
    • Serum Aminotransferase Flares in Pregnant and Postpartum Women With Current or Prior Treatment for Chronic Hepatitis B
    • Chang CY, Aziz N, Poongkunran M, Javaid A, Trinh HN, Lau DT, Nguyen MH. Serum Aminotransferase Flares in Pregnant and Postpartum Women With Current or Prior Treatment for Chronic Hepatitis B. J Clin Gastroenterol 2018;52:255-261.
    • (2018) J Clin Gastroenterol , vol.52 , pp. 255-261
    • Chang, C.Y.1    Aziz, N.2    Poongkunran, M.3    Javaid, A.4    Trinh, H.N.5    Lau, D.T.6    Nguyen, M.H.7
  • 68
    • 84899078129 scopus 로고    scopus 로고
    • Anti-viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post-partum flare
    • Nguyen V, Tan PK, Greenup AJ, Glass A, Davison S, Samarasinghe D, et al. Anti-viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post-partum flare. Aliment Pharmacol Ther 2014;39:1225-1234.
    • (2014) Aliment Pharmacol Ther , vol.39 , pp. 1225-1234
    • Nguyen, V.1    Tan, P.K.2    Greenup, A.J.3    Glass, A.4    Davison, S.5    Samarasinghe, D.6
  • 69
    • 84974851752 scopus 로고    scopus 로고
    • Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load
    • Pan CQ, Duan Z, Dai E, Zhang S, Han G, Wang Y, et al. Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load. N Engl J Med 2016;374:2324-2334.
    • (2016) N Engl J Med , vol.374 , pp. 2324-2334
    • Pan, C.Q.1    Duan, Z.2    Dai, E.3    Zhang, S.4    Han, G.5    Wang, Y.6
  • 70
    • 84938213859 scopus 로고    scopus 로고
    • Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus
    • Chen HL, Lee CN, Chang CH, Ni YH, Shyu MK, Chen SM, et al. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus. Hepatology 2015;62:375-386.
    • (2015) Hepatology , vol.62 , pp. 375-386
    • Chen, H.L.1    Lee, C.N.2    Chang, C.H.3    Ni, Y.H.4    Shyu, M.K.5    Chen, S.M.6
  • 71
    • 84992745690 scopus 로고    scopus 로고
    • Growth at 2 Years of Age in HIV-exposed Uninfected Children in the United States by Trimester of Maternal Antiretroviral Initiation
    • Jacobson DL, Patel K, Williams PL, Geffner ME, Siberry GK, DiMeglio LA, et al. Growth at 2 Years of Age in HIV-exposed Uninfected Children in the United States by Trimester of Maternal Antiretroviral Initiation. Pediatr Infect Dis J 2017;36:189-197.
    • (2017) Pediatr Infect Dis J , vol.36 , pp. 189-197
    • Jacobson, D.L.1    Patel, K.2    Williams, P.L.3    Geffner, M.E.4    Siberry, G.K.5    DiMeglio, L.A.6
  • 72
    • 84973452366 scopus 로고    scopus 로고
    • In Utero Tenofovir Exposure Is not Associated With Fetal Long Bone Growth
    • Jao J, Abrams EJ, Phillips T, Petro G, Zerbe A, Myer L. In Utero Tenofovir Exposure Is not Associated With Fetal Long Bone Growth. Clin Infect Dis 2016;62:1604-1609.
    • (2016) Clin Infect Dis , vol.62 , pp. 1604-1609
    • Jao, J.1    Abrams, E.J.2    Phillips, T.3    Petro, G.4    Zerbe, A.5    Myer, L.6
  • 73
    • 85015202852 scopus 로고    scopus 로고
    • Safety of Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis
    • Nachega JB, Uthman OA, Mofenson LM, Anderson JR, Kanters S, Renaud F, et al. Safety of Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis. J Acquir Immune Defic Syndr 2017;76:1-12.
    • (2017) J Acquir Immune Defic Syndr , vol.76 , pp. 1-12
    • Nachega, J.B.1    Uthman, O.A.2    Mofenson, L.M.3    Anderson, J.R.4    Kanters, S.5    Renaud, F.6
  • 74
    • 84940639472 scopus 로고    scopus 로고
    • Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy
    • Siberry GK, Jacobson DL, Kalkwarf HJ, Wu JW, DiMeglio LA, Yogev R, et al. Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy. Clin Infect Dis 2015;61:996-1003.
    • (2015) Clin Infect Dis , vol.61 , pp. 996-1003
    • Siberry, G.K.1    Jacobson, D.L.2    Kalkwarf, H.J.3    Wu, J.W.4    DiMeglio, L.A.5    Yogev, R.6
  • 76
    • 84894045722 scopus 로고    scopus 로고
    • Risk of vertical transmission of hepatitis B after amniocentesis in HBs antigen-positive mothers
    • Yi W, Pan CQ, Hao J, Hu Y, Liu M, Li L, Liang D. Risk of vertical transmission of hepatitis B after amniocentesis in HBs antigen-positive mothers. J Hepatol 2014;60:523-529.
    • (2014) J Hepatol , vol.60 , pp. 523-529
    • Yi, W.1    Pan, C.Q.2    Hao, J.3    Hu, Y.4    Liu, M.5    Li, L.6    Liang, D.7
  • 77
    • 79952349183 scopus 로고    scopus 로고
    • Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Cote d'Ivoire, in the ANRS 12109 TEmAA Study, Step 2
    • Benaboud S, Pruvost A, Coffie PA, Ekouevi DK, Urien S, Arrive E, et al. Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Cote d'Ivoire, in the ANRS 12109 TEmAA Study, Step 2. Antimicrob Agents Chemother 2011;55:1315-1317.
    • (2011) Antimicrob Agents Chemother , vol.55 , pp. 1315-1317
    • Benaboud, S.1    Pruvost, A.2    Coffie, P.A.3    Ekouevi, D.K.4    Urien, S.5    Arrive, E.6
  • 78
    • 84893795240 scopus 로고    scopus 로고
    • Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life
    • Mirochnick M, Taha T, Kreitchmann R, Nielsen-Saines K, Kumwenda N, Joao E, et al. Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life. J Acquir Immune Defic Syndr 2014;65:33-41.
    • (2014) J Acquir Immune Defic Syndr , vol.65 , pp. 33-41
    • Mirochnick, M.1    Taha, T.2    Kreitchmann, R.3    Nielsen-Saines, K.4    Kumwenda, N.5    Joao, E.6
  • 79
    • 0038392891 scopus 로고    scopus 로고
    • Immunogenicity and safety of two schedules of Hepatitis B vaccination during pregnancy
    • Gupta I, Ratho RK. Immunogenicity and safety of two schedules of Hepatitis B vaccination during pregnancy. J Obstet Gynaecol Res 2003;29:84-86.
    • (2003) J Obstet Gynaecol Res , vol.29 , pp. 84-86
    • Gupta, I.1    Ratho, R.K.2
  • 80
    • 0025871946 scopus 로고
    • Hepatitis B vaccine in pregnancy: maternal and fetal safety
    • Levy M, Koren G. Hepatitis B vaccine in pregnancy: maternal and fetal safety. Am J Perinatol 1991;8:227-232.
    • (1991) Am J Perinatol , vol.8 , pp. 227-232
    • Levy, M.1    Koren, G.2
  • 82
    • 85015355782 scopus 로고    scopus 로고
    • Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older - United States, 2017
    • Kim DK, Riley LE, Harriman KH, Hunter P, Bridges CB. Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older - United States, 2017. MMWR Morb Mortal Wkly Rep. 2017;66:136-138.
    • (2017) MMWR Morb Mortal Wkly Rep. , vol.66 , pp. 136-138
    • Kim, D.K.1    Riley, L.E.2    Harriman, K.H.3    Hunter, P.4    Bridges, C.B.5
  • 83
    • 84871932530 scopus 로고    scopus 로고
    • Hepatitis B vaccination: a completed schedule enough to control HBV lifelong? Milan, Italy, 17-18 November 2011
    • FitzSimons D, Hendrickx G, Vorsters A, Van Damme P. Hepatitis B vaccination: a completed schedule enough to control HBV lifelong? Milan, Italy, 17-18 November 2011. Vaccine 2013;31:584-590.
    • (2013) Vaccine , vol.31 , pp. 584-590
    • FitzSimons, D.1    Hendrickx, G.2    Vorsters, A.3    Van Damme, P.4
  • 84
    • 84908367592 scopus 로고    scopus 로고
    • Epidemiology and Prevention of Vaccine-Preventable Diseases 13th Edition
    • In, eds., Washington, DC, Public Health Foundation
    • Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases 13th Edition. In: Hamborsky J, Kroger A, Wolfe S, eds. The Pink Book. Washington, DC: Public Health Foundation; 2015:157-174.
    • (2015) The Pink Book , pp. 157-174
    • Hamborsky, J.1    Kroger, A.2    Wolfe, S.3
  • 87
    • 84945444443 scopus 로고    scopus 로고
    • Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial
    • Rey D, Piroth L, Wendling MJ, Miailhes P, Michel ML, Dufour C, et al. Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial. Lancet Infect Dis 2015;15:1283-1291.
    • (2015) Lancet Infect Dis , vol.15 , pp. 1283-1291
    • Rey, D.1    Piroth, L.2    Wendling, M.J.3    Miailhes, P.4    Michel, M.L.5    Dufour, C.6
  • 88
    • 84877832031 scopus 로고    scopus 로고
    • Seroprotection after recombinant hepatitis B vaccination among newborn infants: a review
    • Schillie SF, Murphy TV. Seroprotection after recombinant hepatitis B vaccination among newborn infants: a review. Vaccine 2013;31:2506-2516.
    • (2013) Vaccine , vol.31 , pp. 2506-2516
    • Schillie, S.F.1    Murphy, T.V.2
  • 89
    • 85041366861 scopus 로고    scopus 로고
    • Prevention of hepatitis B virus infection in the United States: recommendations of the advisory committee on immunization practices
    • (RR-1)
    • Schillie S, Vellozzi C, Reingold A, Harris A, Haber P, Ward JW, et al. Prevention of hepatitis B virus infection in the United States: recommendations of the advisory committee on immunization practices. MMWR Recomm Rep 2018;67(No. RR-1):1-31.
    • (2018) MMWR Recomm Rep , vol.67 , pp. 1-31
    • Schillie, S.1    Vellozzi, C.2    Reingold, A.3    Harris, A.4    Haber, P.5    Ward, J.W.6
  • 90
    • 40749155059 scopus 로고    scopus 로고
    • Notice to Readers FDA Approval of an Alternate Dosing Schedule for a Combined Hepatitis A and B Vaccine (Twinrix)
    • Center for Disease Control and Prevention. Notice to Readers: FDA Approval of an Alternate Dosing Schedule for a Combined Hepatitis A and B Vaccine (Twinrix). MMWR Morb Mortal Wkly Rep 2007;56:1057.
    • (2007) MMWR Morb Mortal Wkly Rep , vol.56 , pp. 1057
  • 91
    • 84871124169 scopus 로고    scopus 로고
    • Immunizations in chronic liver disease: what should be done and what is the evidence
    • Leise MD, Talwalkar JA. Immunizations in chronic liver disease: what should be done and what is the evidence. Curr Gastroenterol Rep 2013;15:300.
    • (2013) Curr Gastroenterol Rep , vol.15 , pp. 300
    • Leise, M.D.1    Talwalkar, J.A.2
  • 93
    • 84992212809 scopus 로고    scopus 로고
    • Evolution in Our Understanding of Hepatitis B Virus Virology and Immunology
    • Bengsch B, Chang KM. Evolution in Our Understanding of Hepatitis B Virus Virology and Immunology. Clin Liver Dis 2016;20:629-644.
    • (2016) Clin Liver Dis , vol.20 , pp. 629-644
    • Bengsch, B.1    Chang, K.M.2
  • 94
    • 77951483260 scopus 로고    scopus 로고
    • Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology
    • Lee JK, Shim JH, Lee HC, Lee SH, Kim KM, Lim YS, et al. Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology. Hepatology 2010;51:1577-1583.
    • (2010) Hepatology , vol.51 , pp. 1577-1583
    • Lee, J.K.1    Shim, J.H.2    Lee, H.C.3    Lee, S.H.4    Kim, K.M.5    Lim, Y.S.6
  • 95
    • 84856380871 scopus 로고    scopus 로고
    • Upper limits of normal for alanine aminotransferase activity in the United States population
    • Ruhl CE, Everhart JE. Upper limits of normal for alanine aminotransferase activity in the United States population. Hepatology 2012;55:447-454.
    • (2012) Hepatology , vol.55 , pp. 447-454
    • Ruhl, C.E.1    Everhart, J.E.2
  • 97
    • 73149100612 scopus 로고    scopus 로고
    • Variability in the upper limit of normal for serum alanine aminotransferase levels: a statewide study
    • Dutta A, Saha C, Johnson CS, Chalasani N. Variability in the upper limit of normal for serum alanine aminotransferase levels: a statewide study. Hepatology 2009;50:1957-1962.
    • (2009) Hepatology , vol.50 , pp. 1957-1962
    • Dutta, A.1    Saha, C.2    Johnson, C.S.3    Chalasani, N.4
  • 98
    • 41549129499 scopus 로고    scopus 로고
    • Influence of local reference populations on upper limits of normal for serum alanine aminotransferase levels
    • Neuschwander-Tetri BA, Unalp A, Creer MH; Nonalcoholic Steatohepatitis Clinical Research Network. Influence of local reference populations on upper limits of normal for serum alanine aminotransferase levels. Arch Intern Med 2008;168:663-666.
    • (2008) Arch Intern Med , vol.168 , pp. 663-666
    • Neuschwander-Tetri, B.A.1    Unalp, A.2    Creer, M.H.3
  • 99
    • 33947287332 scopus 로고    scopus 로고
    • COBAS AmpliPrep-COBAS TaqMan hepatitis B virus (HBV) test: a novel automated real-time PCR assay for quantification of HBV DNA in plasma
    • Allice T, Cerutti F, Pittaluga F, Varetto S, Gabella S, Marzano A, et al. COBAS AmpliPrep-COBAS TaqMan hepatitis B virus (HBV) test: a novel automated real-time PCR assay for quantification of HBV DNA in plasma. J Clin Microbiol 2007;45:828-834.
    • (2007) J Clin Microbiol , vol.45 , pp. 828-834
    • Allice, T.1    Cerutti, F.2    Pittaluga, F.3    Varetto, S.4    Gabella, S.5    Marzano, A.6
  • 100
    • 0036896285 scopus 로고    scopus 로고
    • Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection
    • Chu CJ, Hussain M, Lok AS. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 2002;36:1408-1415.
    • (2002) Hepatology , vol.36 , pp. 1408-1415
    • Chu, C.J.1    Hussain, M.2    Lok, A.S.3
  • 101
    • 34247194561 scopus 로고    scopus 로고
    • Management of hepatitis B: summary of a clinical research workshop
    • Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007;45:1056-1075.
    • (2007) Hepatology , vol.45 , pp. 1056-1075
    • Hoofnagle, J.H.1    Doo, E.2    Liang, T.J.3    Fleischer, R.4    Lok, A.S.5
  • 102
    • 77951670101 scopus 로고    scopus 로고
    • Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death
    • Chen JD, Yang HI, Iloeje UH, You SL, Lu SN, Wang L, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology 2010;138:1747-1754.
    • (2010) Gastroenterology , vol.138 , pp. 1747-1754
    • Chen, J.D.1    Yang, H.I.2    Iloeje, U.H.3    You, S.L.4    Lu, S.N.5    Wang, L.6
  • 103
    • 85019411425 scopus 로고    scopus 로고
    • Natural history of acute and chronic hepatitis B: the role of HBV genotypes and mutants
    • Lin CL, Kao JH. Natural history of acute and chronic hepatitis B: the role of HBV genotypes and mutants. Best Pract Res Clin Gastroenterol 2017;31:249-255.
    • (2017) Best Pract Res Clin Gastroenterol , vol.31 , pp. 249-255
    • Lin, C.L.1    Kao, J.H.2
  • 104
    • 84876336159 scopus 로고    scopus 로고
    • Hepatitis B virus subgenotyping: history, effects of recombination, misclassifications, and corrections
    • Shi W, Zhang Z, Ling C, Zheng W, Zhu C, Carr MJ, Higgins DG. Hepatitis B virus subgenotyping: history, effects of recombination, misclassifications, and corrections. Infect Genet Evol 2013;16:355-361.
    • (2013) Infect Genet Evol , vol.16 , pp. 355-361
    • Shi, W.1    Zhang, Z.2    Ling, C.3    Zheng, W.4    Zhu, C.5    Carr, M.J.6    Higgins, D.G.7
  • 105
    • 84952700780 scopus 로고    scopus 로고
    • Combination of Tenofovir Disoproxil Fumarate and Peginterferon alpha-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B
    • -1, e10
    • Marcellin P, Ahn SH, Ma X, Caruntu FA, Tak WY, Elkashab M, et al. Combination of Tenofovir Disoproxil Fumarate and Peginterferon alpha-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B. Gastroenterology 2016;150:134-144.e10.
    • (2016) Gastroenterology , vol.44 , pp. 134-150
    • Marcellin, P.1    Ahn, S.H.2    Ma, X.3    Caruntu, F.A.4    Tak, W.Y.5    Elkashab, M.6
  • 106
    • 70649104668 scopus 로고    scopus 로고
    • Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa
    • Buster EH, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW, Janssen HL. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009;137:2002-2009.
    • (2009) Gastroenterology , vol.137 , pp. 2002-2009
    • Buster, E.H.1    Hansen, B.E.2    Lau, G.K.3    Piratvisuth, T.4    Zeuzem, S.5    Steyerberg, E.W.6    Janssen, H.L.7
  • 107
    • 33845636202 scopus 로고    scopus 로고
    • Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma: preponderance of genotype F
    • Livingston SE, Simonetti JP, McMahon BJ, Bulkow LR, Hurlburt KJ, Homan CE, et al. Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma: preponderance of genotype F. J Infect Dis 2007;195:5-11.
    • (2007) J Infect Dis , vol.195 , pp. 5-11
    • Livingston, S.E.1    Simonetti, J.P.2    McMahon, B.J.3    Bulkow, L.R.4    Hurlburt, K.J.5    Homan, C.E.6
  • 108
    • 84986277897 scopus 로고    scopus 로고
    • Incidence of hepatocellular carcinoma according to hepatitis B virus genotype in Alaska Native people
    • Ching LK, Gounder PP, Bulkow L, Spradling PR, Bruce MG, Negus S, et al. Incidence of hepatocellular carcinoma according to hepatitis B virus genotype in Alaska Native people. Liver Int 2016;36:1507-1515.
    • (2016) Liver Int , vol.36 , pp. 1507-1515
    • Ching, L.K.1    Gounder, P.P.2    Bulkow, L.3    Spradling, P.R.4    Bruce, M.G.5    Negus, S.6
  • 110
    • 84962611403 scopus 로고    scopus 로고
    • A Retrospective Study on the Significance of Liver Biopsy and Hepatitis B Surface Antigen in Chronic Hepatitis B Infection
    • Zeng DW, Zhang JM, Liu YR, Dong J, Jiang JJ, Zhu YY. A Retrospective Study on the Significance of Liver Biopsy and Hepatitis B Surface Antigen in Chronic Hepatitis B Infection. Medicine (Baltimore) 2016;95:e2503.
    • (2016) Medicine (Baltimore) , vol.95
    • Zeng, D.W.1    Zhang, J.M.2    Liu, Y.R.3    Dong, J.4    Jiang, J.J.5    Zhu, Y.Y.6
  • 111
    • 84955193798 scopus 로고    scopus 로고
    • Role of serum hepatitis B virus marker quantitation to differentiate natural history phases of HBV infection
    • Wang L, Zou ZQ, Wang K, Yu JG, Liu XZ. Role of serum hepatitis B virus marker quantitation to differentiate natural history phases of HBV infection. Hepatol Int 2016;10:133-138.
    • (2016) Hepatol Int , vol.10 , pp. 133-138
    • Wang, L.1    Zou, Z.Q.2    Wang, K.3    Yu, J.G.4    Liu, X.Z.5
  • 113
    • 84872498407 scopus 로고    scopus 로고
    • Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog
    • Tseng TC, Kao JH. Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog. J Gastroenterol 2013;48:13-21.
    • (2013) J Gastroenterol , vol.48 , pp. 13-21
    • Tseng, T.C.1    Kao, J.H.2
  • 114
    • 85021729548 scopus 로고    scopus 로고
    • Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment
    • Lok AS, Ganova-Raeva L, Cloonan Y, Punkova L, Lin HS, Lee WM, et al. Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment. J Viral Hepat 2017; 24:1032-1042.
    • (2017) J Viral Hepat , vol.24 , pp. 1032-1042
    • Lok, A.S.1    Ganova-Raeva, L.2    Cloonan, Y.3    Punkova, L.4    Lin, H.S.5    Lee, W.M.6
  • 115
    • 84901240677 scopus 로고    scopus 로고
    • Molecular diagnosis and treatment of drug-resistant hepatitis B virus
    • Kim JH, Park YK, Park ES, Kim KH. Molecular diagnosis and treatment of drug-resistant hepatitis B virus. World J Gastroenterol 2014;20:5708-5720.
    • (2014) World J Gastroenterol , vol.20 , pp. 5708-5720
    • Kim, J.H.1    Park, Y.K.2    Park, E.S.3    Kim, K.H.4
  • 116
    • 0020666891 scopus 로고
    • Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis
    • Liaw YF, Chu CM, Su IJ, Huang MJ, Lin DY, Chang-Chien CS. Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. Gastroenterology 1983;84:216-219.
    • (1983) Gastroenterology , vol.84 , pp. 216-219
    • Liaw, Y.F.1    Chu, C.M.2    Su, I.J.3    Huang, M.J.4    Lin, D.Y.5    Chang-Chien, C.S.6
  • 117
    • 0023147172 scopus 로고
    • Changes of serum hepatitis B virus DNA in two types of clinical events preceding spontaneous hepatitis B e antigen seroconversion in chronic type B hepatitis
    • Liaw YF, Pao CC, Chu CM, Sheen IS, Huang MJ. Changes of serum hepatitis B virus DNA in two types of clinical events preceding spontaneous hepatitis B e antigen seroconversion in chronic type B hepatitis. Hepatology 1987;7:1-3.
    • (1987) Hepatology , vol.7 , pp. 1-3
    • Liaw, Y.F.1    Pao, C.C.2    Chu, C.M.3    Sheen, I.S.4    Huang, M.J.5
  • 118
    • 0023243960 scopus 로고
    • Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection
    • Lok AS, Lai CL, Wu PC, Leung EK, Lam TS. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987;92:1839-1843.
    • (1987) Gastroenterology , vol.92 , pp. 1839-1843
    • Lok, A.S.1    Lai, C.L.2    Wu, P.C.3    Leung, E.K.4    Lam, T.S.5
  • 119
    • 0025128658 scopus 로고
    • Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology
    • Lok AS, Lai CL. Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology. J Hepatol 1990;10:29-34.
    • (1990) J Hepatol , vol.10 , pp. 29-34
    • Lok, A.S.1    Lai, C.L.2
  • 120
    • 33846983919 scopus 로고    scopus 로고
    • Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion
    • Chu CM, Liaw YF. Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion. J Viral Hepat 2007;14:147-152.
    • (2007) J Viral Hepat , vol.14 , pp. 147-152
    • Chu, C.M.1    Liaw, Y.F.2
  • 121
    • 84957564464 scopus 로고    scopus 로고
    • Validation of Ten Noninvasive Diagnostic Models for Prediction of Liver Fibrosis in Patients with Chronic Hepatitis B
    • Cheng J, Hou J, Ding H, Chen G, Xie Q, Wang Y, et al. Validation of Ten Noninvasive Diagnostic Models for Prediction of Liver Fibrosis in Patients with Chronic Hepatitis B. PLoS One 2015;10:e0144425.
    • (2015) PLoS One , vol.10
    • Cheng, J.1    Hou, J.2    Ding, H.3    Chen, G.4    Xie, Q.5    Wang, Y.6
  • 122
    • 84924812091 scopus 로고    scopus 로고
    • Transient elastography compared to serum markers to predict liver fibrosis in a cohort of Chinese patients with chronic hepatitis B
    • Jia J, Hou J, Ding H, Chen G, Xie Q, Wang Y, et al. Transient elastography compared to serum markers to predict liver fibrosis in a cohort of Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2015;30:756-762.
    • (2015) J Gastroenterol Hepatol , vol.30 , pp. 756-762
    • Jia, J.1    Hou, J.2    Ding, H.3    Chen, G.4    Xie, Q.5    Wang, Y.6
  • 123
    • 85018815697 scopus 로고    scopus 로고
    • American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases
    • Singh S, Muir AJ, Dieterich DT, Falck-Ytter YT. American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases. Gastroenterology 2017;152:1544-1577.
    • (2017) Gastroenterology , vol.152 , pp. 1544-1577
    • Singh, S.1    Muir, A.J.2    Dieterich, D.T.3    Falck-Ytter, Y.T.4
  • 124
    • 84920972803 scopus 로고    scopus 로고
    • Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis
    • Xiao G, Yang J, Yan L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis. Hepatology 2015;61:292-302.
    • (2015) Hepatology , vol.61 , pp. 292-302
    • Xiao, G.1    Yang, J.2    Yan, L.3
  • 125
    • 0036168816 scopus 로고    scopus 로고
    • Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study
    • Brunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, Gorin JM, Bonino F. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002;36:263-270.
    • (2002) J Hepatol , vol.36 , pp. 263-270
    • Brunetto, M.R.1    Oliveri, F.2    Coco, B.3    Leandro, G.4    Colombatto, P.5    Gorin, J.M.6    Bonino, F.7
  • 127
    • 84979009871 scopus 로고    scopus 로고
    • Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression
    • Liu J, Yang HI, Lee MH, Jen CL, Batrla-Utermann R, Lu SN, et al. Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression. Hepatology 2016;64:381-389.
    • (2016) Hepatology , vol.64 , pp. 381-389
    • Liu, J.1    Yang, H.I.2    Lee, M.H.3    Jen, C.L.4    Batrla-Utermann, R.5    Lu, S.N.6
  • 128
    • 0025753470 scopus 로고
    • Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study
    • Liaw YF, Sheen IS, Chen TJ, Chu CM, Pao CC. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology 1991;13:627-631.
    • (1991) Hepatology , vol.13 , pp. 627-631
    • Liaw, Y.F.1    Sheen, I.S.2    Chen, T.J.3    Chu, C.M.4    Pao, C.C.5
  • 129
    • 34248679355 scopus 로고    scopus 로고
    • HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up
    • Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007;45:1187-1192.
    • (2007) Hepatology , vol.45 , pp. 1187-1192
    • Chu, C.M.1    Liaw, Y.F.2
  • 130
    • 85026823212 scopus 로고    scopus 로고
    • Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance
    • Yip TC, Chan HL, Wong VW, Tse YK, Lam KL, Wong GL. Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. J Hepatol 2017;67:902-908.
    • (2017) J Hepatol , vol.67 , pp. 902-908
    • Yip, T.C.1    Chan, H.L.2    Wong, V.W.3    Tse, Y.K.4    Lam, K.L.5    Wong, G.L.6
  • 131
    • 0036789020 scopus 로고    scopus 로고
    • Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection
    • Chen YC, Sheen IS, Chu CM, Liaw YF. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002;123:1084-1089.
    • (2002) Gastroenterology , vol.123 , pp. 1084-1089
    • Chen, Y.C.1    Sheen, I.S.2    Chu, C.M.3    Liaw, Y.F.4
  • 132
    • 19944434258 scopus 로고    scopus 로고
    • Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance
    • Ahn SH, Park YN, Park JY, Chang HY, Lee JM, Shin JE, et al. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J Hepatol 2005;42:188-194.
    • (2005) J Hepatol , vol.42 , pp. 188-194
    • Ahn, S.H.1    Park, Y.N.2    Park, J.Y.3    Chang, H.Y.4    Lee, J.M.5    Shin, J.E.6
  • 134
    • 28844480321 scopus 로고    scopus 로고
    • Management of hepatocellular carcinoma
    • Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236.
    • (2005) Hepatology , vol.42 , pp. 1208-1236
    • Bruix, J.1    Sherman, M.2
  • 135
    • 85005900893 scopus 로고    scopus 로고
    • Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection
    • Chayanupatkul M, Omino R, Mittal S, Kramer JR, Richardson P, Thrift AP, et al. Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection. J Hepatol 2017;66:355-362.
    • (2017) J Hepatol , vol.66 , pp. 355-362
    • Chayanupatkul, M.1    Omino, R.2    Mittal, S.3    Kramer, J.R.4    Richardson, P.5    Thrift, A.P.6
  • 136
    • 85031670161 scopus 로고    scopus 로고
    • Influence of Metabolic Risk Factors on Risk of Hepatocellular Carcinoma and Liver-Related Death in Men With Chronic Hepatitis B: A Large Cohort Study
    • Yu MW, Lin CL, Liu CJ, Yang SH, Tseng YL, Wu CF. Influence of Metabolic Risk Factors on Risk of Hepatocellular Carcinoma and Liver-Related Death in Men With Chronic Hepatitis B: A Large Cohort Study. Gastroenterology 2017;153:1006-1017.e5.
    • (2017) Gastroenterology , vol.153 , pp. 1006-1017.e5
    • Yu, M.W.1    Lin, C.L.2    Liu, C.J.3    Yang, S.H.4    Tseng, Y.L.5    Wu, C.F.6
  • 137
    • 84949625768 scopus 로고    scopus 로고
    • Mediation Analysis of Hepatitis B and C in Relation to Hepatocellular Carcinoma Risk
    • Huang YT, Yang HI, Liu J, Lee MH, Freeman JR, Chen CJ. Mediation Analysis of Hepatitis B and C in Relation to Hepatocellular Carcinoma Risk. Epidemiology 2016;27:14-20.
    • (2016) Epidemiology , vol.27 , pp. 14-20
    • Huang, Y.T.1    Yang, H.I.2    Liu, J.3    Lee, M.H.4    Freeman, J.R.5    Chen, C.J.6
  • 138
    • 84872144438 scopus 로고    scopus 로고
    • The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection
    • Ioannou GN, Bryson CL, Weiss NS, Miller R, Scott JD, Boyko EJ. The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology 2013;57:249-257.
    • (2013) Hepatology , vol.57 , pp. 249-257
    • Ioannou, G.N.1    Bryson, C.L.2    Weiss, N.S.3    Miller, R.4    Scott, J.D.5    Boyko, E.J.6
  • 139
    • 7044272630 scopus 로고    scopus 로고
    • Hepatocellular carcinoma in cirrhosis: incidence and risk factors
    • Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127(5Suppl1):S35-S50.
    • (2004) Gastroenterology , vol.1275Suppl1 , pp. S35-S50
    • Fattovich, G.1    Stroffolini, T.2    Zagni, I.3    Donato, F.4
  • 141
    • 84872097828 scopus 로고    scopus 로고
    • Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus
    • Kim YJ, Lee JW, Kim YS, Jeong SH, Kim YS, Yim HJ, et al. Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus. Korean J Hepatol 2011;17:199-205.
    • (2011) Korean J Hepatol , vol.17 , pp. 199-205
    • Kim, Y.J.1    Lee, J.W.2    Kim, Y.S.3    Jeong, S.H.4    Kim, Y.S.5    Yim, H.J.6
  • 143
    • 84984585800 scopus 로고    scopus 로고
    • Peginterferon Alfa-2a Plus Ribavirin for the Treatment of Dual Chronic Infection With Hepatitis B and C Viruses
    • Liu CJ, Chuang WL, Lee CM, Yu ML, Lu SN, Wu SS, et al. Peginterferon Alfa-2a Plus Ribavirin for the Treatment of Dual Chronic Infection With Hepatitis B and C Viruses. Gastroenterology 2008;136:496-504.e3.
    • (2008) Gastroenterology , vol.136 , pp. 496-504.e3
    • Liu, C.J.1    Chuang, W.L.2    Lee, C.M.3    Yu, M.L.4    Lu, S.N.5    Wu, S.S.6
  • 144
    • 53349148149 scopus 로고    scopus 로고
    • The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection
    • Potthoff A, Wedemeyer H, Boecher WO, Berg T, Zeuzem S, Arnold J, et al. The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol 2008;49:688-694.
    • (2008) J Hepatol , vol.49 , pp. 688-694
    • Potthoff, A.1    Wedemeyer, H.2    Boecher, W.O.3    Berg, T.4    Zeuzem, S.5    Arnold, J.6
  • 145
    • 85002245074 scopus 로고    scopus 로고
    • Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-acting Antiviral Agents
    • Wang C, Ji D, Chen J, Shao Q, Li B, Liu J, et al. Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-acting Antiviral Agents. Clin Gastroenterol Hepatol 2017;15:132-136.
    • (2017) Clin Gastroenterol Hepatol , vol.15 , pp. 132-136
    • Wang, C.1    Ji, D.2    Chen, J.3    Shao, Q.4    Li, B.5    Liu, J.6
  • 146
    • 85020750860 scopus 로고    scopus 로고
    • Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System
    • Bersoff-Matcha SJ, Cao K, Jason M, Ajao A, Jones SC, Meyer T, Brinker A. Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System. Ann Intern Med 2017;166:792-798.
    • (2017) Ann Intern Med , vol.166 , pp. 792-798
    • Bersoff-Matcha, S.J.1    Cao, K.2    Jason, M.3    Ajao, A.4    Jones, S.C.5    Meyer, T.6    Brinker, A.7
  • 147
    • 85019264254 scopus 로고    scopus 로고
    • Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals
    • Belperio PS, Shahoumian TA, Mole LA, Backus LI. Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals. Hepatology 2017;66:27-36.
    • (2017) Hepatology , vol.66 , pp. 27-36
    • Belperio, P.S.1    Shahoumian, T.A.2    Mole, L.A.3    Backus, L.I.4
  • 148
    • 85017518282 scopus 로고    scopus 로고
    • Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: a systematic review and meta-analysis
    • Chen G, Wang C, Chen J, Ji D, Wang Y, Wu V, et al. Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: a systematic review and meta-analysis. Hepatology 2017;66:13-26.
    • (2017) Hepatology , vol.66 , pp. 13-26
    • Chen, G.1    Wang, C.2    Chen, J.3    Ji, D.4    Wang, Y.5    Wu, V.6
  • 150
    • 85044261351 scopus 로고    scopus 로고
    • Geneva, Switzerland; World Health Organization;
    • World Health Organization. Hepatitis D: Fact Sheet. In: Media Centre. Geneva, Switzerland; World Health Organization; 2017.
    • (2017) Hepatitis D Fact Sheet. In Media Centre
  • 152
    • 33748943782 scopus 로고    scopus 로고
    • Efficacy of peginterferon alfa-2b in chronic delta hepatitis.Relevance of quantitative RT-PCR for follow-up
    • Castelnau C, Le Gal F, Ripault M, Gordien E, Martinot-Peignoux M, Boyer N, et al. Efficacy of peginterferon alfa-2b in chronic delta hepatitis.Relevance of quantitative RT-PCR for follow-up. Hepatology 2006;44:728-735.
    • (2006) Hepatology , vol.44 , pp. 728-735
    • Castelnau, C.1    Le Gal, F.2    Ripault, M.3    Gordien, E.4    Martinot-Peignoux, M.5    Boyer, N.6
  • 154
    • 84906887425 scopus 로고    scopus 로고
    • Treatment of chronic hepatitis D patients with pegylated interferon: a real-world experience
    • Abbas Z, Memon MS, Mithani H, Jafri W, Hamid S. Treatment of chronic hepatitis D patients with pegylated interferon: a real-world experience. Antivir Ther 2014;19:463-468.
    • (2014) Antivir Ther , vol.19 , pp. 463-468
    • Abbas, Z.1    Memon, M.S.2    Mithani, H.3    Jafri, W.4    Hamid, S.5
  • 155
    • 84902091591 scopus 로고    scopus 로고
    • Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta
    • Heidrich B, Yurdaydin C, Kabacam G, Ratsch BA, Zachou K, Bremer B, et al. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology 2014;60:87-97.
    • (2014) Hepatology , vol.60 , pp. 87-97
    • Heidrich, B.1    Yurdaydin, C.2    Kabacam, G.3    Ratsch, B.A.4    Zachou, K.5    Bremer, B.6
  • 157
    • 84947244327 scopus 로고    scopus 로고
    • Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome
    • Keskin O, Wedemeyer H, Tuzun A, Zachou K, Deda X, Dalekos GN, et al. Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome. Clin Gastroenterol Hepatol 2015;13:2342-2349.e1-2.
    • (2015) Clin Gastroenterol Hepatol , vol.13 , pp. 2342-2349.e1-2
    • Keskin, O.1    Wedemeyer, H.2    Tuzun, A.3    Zachou, K.4    Deda, X.5    Dalekos, G.N.6
  • 158
    • 84979663414 scopus 로고    scopus 로고
    • Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib/IIa study
    • Bogomolov P, Alexandrov A, Voronkova N, Macievich M, Kokina K, Petrachenkova M, et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib/IIa study. J Hepatol 2016;65:490-498.
    • (2016) J Hepatol , vol.65 , pp. 490-498
    • Bogomolov, P.1    Alexandrov, A.2    Voronkova, N.3    Macievich, M.4    Kokina, K.5    Petrachenkova, M.6
  • 159
    • 84942199484 scopus 로고    scopus 로고
    • Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial
    • Koh C, Canini L, Dahari H, Zhao X, Uprichard SL, Haynes-Williams V, et al. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infect Dis 2015;15:1167-1174.
    • (2015) Lancet Infect Dis , vol.15 , pp. 1167-1174
    • Koh, C.1    Canini, L.2    Dahari, H.3    Zhao, X.4    Uprichard, S.L.5    Haynes-Williams, V.6
  • 160
    • 1842607685 scopus 로고    scopus 로고
    • Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus
    • Dore GJ, Cooper DA, Pozniak AL, DeJesus E, Zhong L, Miller MD, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004;189:1185-1192.
    • (2004) J Infect Dis , vol.189 , pp. 1185-1192
    • Dore, G.J.1    Cooper, D.A.2    Pozniak, A.L.3    DeJesus, E.4    Zhong, L.5    Miller, M.D.6
  • 161
    • 0035867080 scopus 로고    scopus 로고
    • Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens
    • Hoff J, Bani-Sadr F, Gassin M, Raffi F. Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens. Clin Infect Dis 2001;32:963-969.
    • (2001) Clin Infect Dis , vol.32 , pp. 963-969
    • Hoff, J.1    Bani-Sadr, F.2    Gassin, M.3    Raffi, F.4
  • 162
    • 0032760120 scopus 로고    scopus 로고
    • Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients
    • Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999;30:1302-1306.
    • (1999) Hepatology , vol.30 , pp. 1302-1306
    • Benhamou, Y.1    Bochet, M.2    Thibault, V.3    Di Martino, V.4    Caumes, E.5    Bricaire, F.6
  • 163
    • 85044296210 scopus 로고    scopus 로고
    • Washington, DC Department of Health and Human Services;
    • Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Washington, DC: Department of Health and Human Services; 2016.
    • (2016) Hepatitis D Fact Sheet. In Media Centre
  • 164
    • 84966709419 scopus 로고    scopus 로고
    • Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults
    • Gallant J, Brunetta J, Crofoot G, Benson P, Mills A, Brinson C, et al. Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults. J Acquir Immune Defic Syndr 2016;73:294-298.
    • (2016) J Acquir Immune Defic Syndr , vol.73 , pp. 294-298
    • Gallant, J.1    Brunetta, J.2    Crofoot, G.3    Benson, P.4    Mills, A.5    Brinson, C.6
  • 165
    • 84960824872 scopus 로고    scopus 로고
    • Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial
    • Gallant JE, Daar ES, Raffi F, Brinson C, Ruane P, DeJesus E, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. Lancet HIV 2016;3:e158-e165.
    • (2016) Lancet HIV , vol.3 , pp. e158-e165
    • Gallant, J.E.1    Daar, E.S.2    Raffi, F.3    Brinson, C.4    Ruane, P.5    DeJesus, E.6
  • 166
    • 84991493062 scopus 로고    scopus 로고
    • A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults
    • Huhn GD, Tebas P, Gallant J, Wilkin T, Cheng A, Yan M, et al. A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults. J Acquir Immune Defic Syndr 2017;74:193-200.
    • (2017) J Acquir Immune Defic Syndr , vol.74 , pp. 193-200
    • Huhn, G.D.1    Tebas, P.2    Gallant, J.3    Wilkin, T.4    Cheng, A.5    Yan, M.6
  • 168
    • 0035136225 scopus 로고    scopus 로고
    • Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy
    • Manegold C, Hannoun C, Wywiol A, Dietrich M, Polywka S, Chiwakata CB, Gunther S. Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy. Clin Infect Dis 2001;32:144-148.
    • (2001) Clin Infect Dis , vol.32 , pp. 144-148
    • Manegold, C.1    Hannoun, C.2    Wywiol, A.3    Dietrich, M.4    Polywka, S.5    Chiwakata, C.B.6    Gunther, S.7
  • 169
    • 0034606721 scopus 로고    scopus 로고
    • Hepatotoxicity associated with antiretroviral therapy in adults infected with human immumodeficiency virus and the role of hepatitis C and B virus infection
    • Sulkowski MS, Thomas D, Chaisson R, Moore R. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immumodeficiency virus and the role of hepatitis C and B virus infection. JAMA 2000;283:74-80.
    • (2000) JAMA , vol.283 , pp. 74-80
    • Sulkowski, M.S.1    Thomas, D.2    Chaisson, R.3    Moore, R.4
  • 170
    • 0034523342 scopus 로고    scopus 로고
    • Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection
    • den Brinker M, Wit FW, Wertheim-van Dillen PM, Jurriaans S, Weel J, van Leeuwen R, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000;14:2895-2902.
    • (2000) AIDS , vol.14 , pp. 2895-2902
    • den Brinker, M.1    Wit, F.W.2    Wertheim-van Dillen, P.M.3    Jurriaans, S.4    Weel, J.5    van Leeuwen, R.6
  • 171
    • 0026088152 scopus 로고
    • Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study
    • Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991;100:182-188.
    • (1991) Gastroenterology , vol.100 , pp. 182-188
    • Lok, A.S.1    Liang, R.H.2    Chiu, E.K.3    Wong, K.L.4    Chan, T.K.5    Todd, D.6
  • 172
    • 0033804328 scopus 로고    scopus 로고
    • Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors
    • Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000;62:299-307.
    • (2000) J Med Virol , vol.62 , pp. 299-307
    • Yeo, W.1    Chan, P.K.2    Zhong, S.3    Ho, W.M.4    Steinberg, J.L.5    Tam, J.S.6
  • 173
    • 9444277289 scopus 로고    scopus 로고
    • Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy
    • Yeo W, Lam KC, Zee B, Chan PS, Mo FK, Ho WM, et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol 2004;15:1661-1666.
    • (2004) Ann Oncol , vol.15 , pp. 1661-1666
    • Yeo, W.1    Lam, K.C.2    Zee, B.3    Chan, P.S.4    Mo, F.K.5    Ho, W.M.6
  • 174
    • 33644514992 scopus 로고    scopus 로고
    • A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization
    • Jang JW, Choi JY, Bae SH, Yoon SK, Chang UI, Kim CW, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 2006;43:233-240.
    • (2006) Hepatology , vol.43 , pp. 233-240
    • Jang, J.W.1    Choi, J.Y.2    Bae, S.H.3    Yoon, S.K.4    Chang, U.I.5    Kim, C.W.6
  • 175
    • 33745753570 scopus 로고    scopus 로고
    • Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy
    • Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006;131:59-68.
    • (2006) Gastroenterology , vol.131 , pp. 59-68
    • Hui, C.K.1    Cheung, W.W.2    Zhang, H.Y.3    Au, W.Y.4    Yueng, Y.H.5    Leung, A.Y.6
  • 176
    • 29844443111 scopus 로고    scopus 로고
    • Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients
    • Hsiao LT, Chiou TJ, Liu JH, Chu CJ, Lin YC, Chao TC, et al. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2006;12:84-94.
    • (2006) Biol Blood Marrow Transplant , vol.12 , pp. 84-94
    • Hsiao, L.T.1    Chiou, T.J.2    Liu, J.H.3    Chu, C.J.4    Lin, Y.C.5    Chao, T.C.6
  • 177
    • 42249113025 scopus 로고    scopus 로고
    • Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy
    • Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, Csako G. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008;148:519-528.
    • (2008) Ann Intern Med , vol.148 , pp. 519-528
    • Loomba, R.1    Rowley, A.2    Wesley, R.3    Liang, T.J.4    Hoofnagle, J.H.5    Pucino, F.6    Csako, G.7
  • 178
    • 84953207576 scopus 로고    scopus 로고
    • Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor Chemotherapy: A Systematic Review and Meta-analysis
    • Paul S, Saxena A, Terrin N, Viveiros K, Balk EM, Wong JB. Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor Chemotherapy: A Systematic Review and Meta-analysis. Ann Intern Med 2016;164:30-40.
    • (2016) Ann Intern Med , vol.164 , pp. 30-40
    • Paul, S.1    Saxena, A.2    Terrin, N.3    Viveiros, K.4    Balk, E.M.5    Wong, J.B.6
  • 179
    • 10744222282 scopus 로고    scopus 로고
    • Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy
    • Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003;125:1742-1749.
    • (2003) Gastroenterology , vol.125 , pp. 1742-1749
    • Lau, G.K.1    Yiu, H.H.2    Fong, D.Y.3    Cheng, H.C.4    Au, W.Y.5    Lai, L.S.6
  • 181
    • 84886524794 scopus 로고    scopus 로고
    • Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs
    • Lee YH, Bae SC, Song GG. Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs. Int J Rheum Dis 2013;16:527-531.
    • (2013) Int J Rheum Dis , vol.16 , pp. 527-531
    • Lee, Y.H.1    Bae, S.C.2    Song, G.G.3
  • 182
    • 84942320360 scopus 로고    scopus 로고
    • Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations
    • Mori S, Fujiyama S. Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations. World J Gastroenterol 2015;21:10274-10289.
    • (2015) World J Gastroenterol , vol.21 , pp. 10274-10289
    • Mori, S.1    Fujiyama, S.2
  • 183
    • 84866356153 scopus 로고    scopus 로고
    • Significant rate of hepatitis B reactivation following kidney transplantation in patients with resolved infection
    • Kanaan N, Kabamba B, Maréchal C, Pirson Y, Beguin C, Goffin E, Hassoun Z. Significant rate of hepatitis B reactivation following kidney transplantation in patients with resolved infection. J Clin Virol 2012;55:233-238.
    • (2012) J Clin Virol , vol.55 , pp. 233-238
    • Kanaan, N.1    Kabamba, B.2    Maréchal, C.3    Pirson, Y.4    Beguin, C.5    Goffin, E.6    Hassoun, Z.7
  • 184
    • 20144378361 scopus 로고    scopus 로고
    • Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection
    • Onozawa M, Hashino S, Izumiyama K, Kahata K, Chuma M, Mori A, et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 2005;79:616-619.
    • (2005) Transplantation , vol.79 , pp. 616-619
    • Onozawa, M.1    Hashino, S.2    Izumiyama, K.3    Kahata, K.4    Chuma, M.5    Mori, A.6
  • 186
    • 84862664371 scopus 로고    scopus 로고
    • EASL clinical practice guidelines: Management of chronic hepatitis B virus infection
    • European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-185.
    • (2012) J Hepatol , vol.57 , pp. 167-185
  • 187
    • 84984562922 scopus 로고    scopus 로고
    • Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
    • Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016;10:1-98.
    • (2016) Hepatol Int , vol.10 , pp. 1-98
    • Sarin, S.K.1    Kumar, M.2    Lau, G.K.3    Abbas, Z.4    Chan, H.L.5    Chen, C.J.6
  • 190
    • 84930003792 scopus 로고    scopus 로고
    • Poor recognition of risk factors for hepatitis B by physicians prescribing immunosuppressive therapy: a call for universal rather than risk-based screening
    • Visram A, Chan KK, McGee P, Boro J, Hicks LK, Feld JJ. Poor recognition of risk factors for hepatitis B by physicians prescribing immunosuppressive therapy: a call for universal rather than risk-based screening. PLoS One 2015;10:e0120749.
    • (2015) PLoS One , vol.10
    • Visram, A.1    Chan, K.K.2    McGee, P.3    Boro, J.4    Hicks, L.K.5    Feld, J.J.6
  • 191
    • 85044276851 scopus 로고    scopus 로고
    • Models to Predict Hepatitis B Virus Infection among Patients with Cancer Undergoing Systemic Anti-cancer Therapy A Prospective Cohort Study
    • Washington, DC
    • Hwang JP, Lok A, Fisch MJ, Cantor SB, Barbo AG, Lin HY, et al. Models to Predict Hepatitis B Virus Infection among Patients with Cancer Undergoing Systemic Anti-cancer Therapy: A Prospective Cohort Study. In: Society of General Internal Medicine Annual Meeting, Washington, DC, 2017.
    • (2017) In Society of General Internal Medicine Annual Meeting
    • Hwang, J.P.1    Lok, A.2    Fisch, M.J.3    Cantor, S.B.4    Barbo, A.G.5    Lin, H.Y.6
  • 192
    • 84922858375 scopus 로고    scopus 로고
    • American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy
    • Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015;148:221-244.e3.
    • (2015) Gastroenterology , vol.148 , pp. 221-244.e3
    • Perrillo, R.P.1    Gish, R.2    Falck-Ytter, Y.T.3
  • 193
    • 85017387311 scopus 로고    scopus 로고
    • Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment
    • Voican CS, Mir O, Loulergue P, Dhooge M, Brezault C, Dréanic J, et al. Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment. Ann Oncol 2016;27:2172-2184.
    • (2016) Ann Oncol , vol.27 , pp. 2172-2184
    • Voican, C.S.1    Mir, O.2    Loulergue, P.3    Dhooge, M.4    Brezault, C.5    Dréanic, J.6
  • 194
    • 79955875687 scopus 로고    scopus 로고
    • Why, when, and how to prevent hepatitis B virus reactivation in cancer patients undergoing chemotherapy
    • Keam B, Lee JH, Im SA, Yoon JH. Why, when, and how to prevent hepatitis B virus reactivation in cancer patients undergoing chemotherapy. J Natl Compr Cancer Netw 2011;9:465-477.
    • (2011) J Natl Compr Cancer Netw , vol.9 , pp. 465-477
    • Keam, B.1    Lee, J.H.2    Im, S.A.3    Yoon, J.H.4
  • 195
    • 2342560548 scopus 로고    scopus 로고
    • Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy
    • Yeo W, Zee B, Zhong S, Chan PK, Wong WL, Ho WM, et al. Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004;90:1306-1311.
    • (2004) Br J Cancer , vol.90 , pp. 1306-1311
    • Yeo, W.1    Zee, B.2    Zhong, S.3    Chan, P.K.4    Wong, W.L.5    Ho, W.M.6
  • 196
    • 0036530048 scopus 로고    scopus 로고
    • High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation
    • Lau GK, Leung YH, Fong DY, Au WY, Kwong YL, Lie A, et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 2002;99:2324-2330.
    • (2002) Blood , vol.99 , pp. 2324-2330
    • Lau, G.K.1    Leung, Y.H.2    Fong, D.Y.3    Au, W.Y.4    Kwong, Y.L.5    Lie, A.6
  • 197
    • 40949125163 scopus 로고    scopus 로고
    • A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial
    • Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, Lin SF, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology 2008;47:844-853.
    • (2008) Hepatology , vol.47 , pp. 844-853
    • Hsu, C.1    Hsiung, C.A.2    Su, I.J.3    Hwang, W.S.4    Wang, M.C.5    Lin, S.F.6
  • 198
    • 84933178530 scopus 로고    scopus 로고
    • Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection
    • Barone M, Notarnicola A, Lopalco G, Viggiani MT, Sebastiani F, Covelli M, et al. Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection. Hepatology 2015;62:40-46.
    • (2015) Hepatology , vol.62 , pp. 40-46
    • Barone, M.1    Notarnicola, A.2    Lopalco, G.3    Viggiani, M.T.4    Sebastiani, F.5    Covelli, M.6
  • 199
    • 84969269080 scopus 로고    scopus 로고
    • Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study
    • Varisco V, Vigano M, Batticciotto A, Lampertico P, Marchesoni A, Gibertini P, et al. Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study. J Rheumatol 2016;43:869-874.
    • (2016) J Rheumatol , vol.43 , pp. 869-874
    • Varisco, V.1    Vigano, M.2    Batticciotto, A.3    Lampertico, P.4    Marchesoni, A.5    Gibertini, P.6
  • 200
    • 79959848770 scopus 로고    scopus 로고
    • Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts
    • Tamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H, et al. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol 2011;46:556-564.
    • (2011) J Gastroenterol , vol.46 , pp. 556-564
    • Tamori, A.1    Koike, T.2    Goto, H.3    Wakitani, S.4    Tada, M.5    Morikawa, H.6
  • 201
    • 84872495292 scopus 로고    scopus 로고
    • Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-alpha agents
    • Papa A, Felice C, Marzo M, Andrisani G, Armuzzi A, Covino M, et al. Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-alpha agents. J Crohns Colitis 2013;7:113-119.
    • (2013) J Crohns Colitis , vol.7 , pp. 113-119
    • Papa, A.1    Felice, C.2    Marzo, M.3    Andrisani, G.4    Armuzzi, A.5    Covino, M.6
  • 202
    • 84964314209 scopus 로고    scopus 로고
    • Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis
    • Morisco F, Guarino M, La Bella S, Di Costanzo L, Caporaso N, Ayala F, Balato N. Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis. BMC Gastroenterol 2014;14:214.
    • (2014) BMC Gastroenterol , vol.14 , pp. 214
    • Morisco, F.1    Guarino, M.2    La Bella, S.3    Di Costanzo, L.4    Caporaso, N.5    Ayala, F.6    Balato, N.7
  • 203
    • 84911424291 scopus 로고    scopus 로고
    • Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study
    • Seto WK, Chan TS, Hwang YY, Wong DK, Fung J, Liu KS, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol 2014;32:3736-3743.
    • (2014) J Clin Oncol , vol.32 , pp. 3736-3743
    • Seto, W.K.1    Chan, T.S.2    Hwang, Y.Y.3    Wong, D.K.4    Fung, J.5    Liu, K.S.6
  • 204
    • 84896695494 scopus 로고    scopus 로고
    • Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma
    • Masarone M, De Renzo A, La Mura V, Sasso FC, Romano M, Signoriello G, et al. Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma. BMC Gastroenterol 2014;14:31.
    • (2014) BMC Gastroenterol , vol.14 , pp. 31
    • Masarone, M.1    De Renzo, A.2    La Mura, V.3    Sasso, F.C.4    Romano, M.5    Signoriello, G.6
  • 205
    • 84971519421 scopus 로고    scopus 로고
    • Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation
    • Zhang MY, Zhu GQ, Shi KQ, Zheng JN, Cheng Z, Zou ZL, et al. Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation. Oncotarget 2016;7:30642-30658.
    • (2016) Oncotarget , vol.7 , pp. 30642-30658
    • Zhang, M.Y.1    Zhu, G.Q.2    Shi, K.Q.3    Zheng, J.N.4    Cheng, Z.5    Zou, Z.L.6
  • 206
    • 84971422844 scopus 로고    scopus 로고
    • Meta-analysis of prophylactic entecavir or lamivudine against hepatitis B virus reactivation
    • Yang C, Qin B, Yuan Z, Chen L, Zhou HY. Meta-analysis of prophylactic entecavir or lamivudine against hepatitis B virus reactivation. Ann Hepatol 2016;15:501-511.
    • (2016) Ann Hepatol , vol.15 , pp. 501-511
    • Yang, C.1    Qin, B.2    Yuan, Z.3    Chen, L.4    Zhou, H.Y.5
  • 207
    • 84979595922 scopus 로고    scopus 로고
    • Comparison of entecavir and lamivudine in preventing HBV reactivation in lymphoma patients undergoing chemotherapy: a meta-analysis
    • Yu S, Luo H, Pan M, Luis AP, Xiong Z, Shuai P, Zhang Z. Comparison of entecavir and lamivudine in preventing HBV reactivation in lymphoma patients undergoing chemotherapy: a meta-analysis. Int J Clin Pharm 2016;38:1035-1043.
    • (2016) Int J Clin Pharm , vol.38 , pp. 1035-1043
    • Yu, S.1    Luo, H.2    Pan, M.3    Luis, A.P.4    Xiong, Z.5    Shuai, P.6    Zhang, Z.7
  • 208
    • 84995390477 scopus 로고    scopus 로고
    • Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor
    • Cerva C, Colagrossi L, Maffongelli G, Salpini R, Di Carlo D, Malagnino V, et al. Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor. Clin Microbiol Infect 2016;22:946.e1-946.e8.
    • (2016) Clin Microbiol Infect , vol.22 , pp. 946.e1-946.e8
    • Cerva, C.1    Colagrossi, L.2    Maffongelli, G.3    Salpini, R.4    Di Carlo, D.5    Malagnino, V.6
  • 209
    • 84953321100 scopus 로고    scopus 로고
    • Hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy in patients with diffuse large B cell lymphoma
    • Liu WP, Wang XP, Zheng W, Ping LY, Zhang C, Wang GQ, et al. Hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy in patients with diffuse large B cell lymphoma. Leuk Lymphoma 2016;57:1355-1362.
    • (2016) Leuk Lymphoma , vol.57 , pp. 1355-1362
    • Liu, W.P.1    Wang, X.P.2    Zheng, W.3    Ping, L.Y.4    Zhang, C.5    Wang, G.Q.6
  • 210
    • 84988528118 scopus 로고    scopus 로고
    • Delayed HBV reactivation in rituximab-containing chemotherapy: how long should we continue anti-virus prophylaxis or monitoring HBV-DNA?
    • Nakaya A, Fujita S, Satake A, Nakanishi T, Azuma Y, Tsubokura Y, et al. Delayed HBV reactivation in rituximab-containing chemotherapy: how long should we continue anti-virus prophylaxis or monitoring HBV-DNA? Leuk Res 2016;50:46-49.
    • (2016) Leuk Res , vol.50 , pp. 46-49
    • Nakaya, A.1    Fujita, S.2    Satake, A.3    Nakanishi, T.4    Azuma, Y.5    Tsubokura, Y.6
  • 211
    • 84860389757 scopus 로고    scopus 로고
    • Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence
    • Lenci I, Tisone G, Di Paolo D, Marcuccilli F, Tariciotti L, Ciotti M, et al. Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence. J Hepatol 2011;55:587-593.
    • (2011) J Hepatol , vol.55 , pp. 587-593
    • Lenci, I.1    Tisone, G.2    Di Paolo, D.3    Marcuccilli, F.4    Tariciotti, L.5    Ciotti, M.6
  • 212
    • 78650657357 scopus 로고    scopus 로고
    • Hepatitis B virus infection and immunosuppressive therapy in patients with inflammatory bowel disease
    • Morisco F, Castiglione F, Rispo A, Stroffolini T, Vitale R, Sansone S, et al. Hepatitis B virus infection and immunosuppressive therapy in patients with inflammatory bowel disease. Dig Liver Dis 2011;43(Suppl 1):S40-S48.
    • (2011) Dig Liver Dis , vol.43 , pp. S40-S48
    • Morisco, F.1    Castiglione, F.2    Rispo, A.3    Stroffolini, T.4    Vitale, R.5    Sansone, S.6
  • 213
    • 84897959215 scopus 로고    scopus 로고
    • Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection
    • Cho JH, Lim JH, Park GY, Kim JS, Kang YJ, Kwon O, et al. Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection. Transpl Infect Dis 2014;16:295-303.
    • (2014) Transpl Infect Dis , vol.16 , pp. 295-303
    • Cho, J.H.1    Lim, J.H.2    Park, G.Y.3    Kim, J.S.4    Kang, Y.J.5    Kwon, O.6
  • 214
    • 84897988099 scopus 로고    scopus 로고
    • Management of patients with hepatitis B who require immunosuppressive therapy
    • Hwang JP, Lok AS. Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol 2014;11:209-219.
    • (2014) Nat Rev Gastroenterol Hepatol , vol.11 , pp. 209-219
    • Hwang, J.P.1    Lok, A.S.2
  • 215
    • 5044234176 scopus 로고    scopus 로고
    • The use of lamivudine for patients with acute hepatitis B (a series of cases)
    • Kondili LA, Osman H, Mutimer D. The use of lamivudine for patients with acute hepatitis B (a series of cases). J Viral Hepat 2004;11:427-431.
    • (2004) J Viral Hepat , vol.11 , pp. 427-431
    • Kondili, L.A.1    Osman, H.2    Mutimer, D.3
  • 216
    • 33645083207 scopus 로고    scopus 로고
    • Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience
    • Tillmann HL, Hadem J, Leifeld L, Zachou K, Canbay A, Eisenbach C, et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat 2006;13:256-263.
    • (2006) J Viral Hepat , vol.13 , pp. 256-263
    • Tillmann, H.L.1    Hadem, J.2    Leifeld, L.3    Zachou, K.4    Canbay, A.5    Eisenbach, C.6
  • 217
    • 33846447769 scopus 로고    scopus 로고
    • A randomized controlled trial of lamivudine to treat acute hepatitis B
    • Kumar M, Satapathy S, Monga R, Das K, Hissar S, Pande C, et al. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology 2007;45:97-101.
    • (2007) Hepatology , vol.45 , pp. 97-101
    • Kumar, M.1    Satapathy, S.2    Monga, R.3    Das, K.4    Hissar, S.5    Pande, C.6
  • 218
    • 0037564938 scopus 로고    scopus 로고
    • Excellent outcome of Lamivudine treatment in patients with chronic renal failure and hepatitis B virus infection
    • Schmilovitz-Weiss H, Melzer E, Tur-Kaspa R, Ben-Ari Z. Excellent outcome of Lamivudine treatment in patients with chronic renal failure and hepatitis B virus infection. J Clin Gastroenterol 2003;37:64-67.
    • (2003) J Clin Gastroenterol , vol.37 , pp. 64-67
    • Schmilovitz-Weiss, H.1    Melzer, E.2    Tur-Kaspa, R.3    Ben-Ari, Z.4
  • 219
    • 0035010523 scopus 로고    scopus 로고
    • Management of hepatitis B: 2000—Summary of a Workshop
    • Lok AS, Heattcote EJ, Hoofnagle JH. Management of hepatitis B: 2000—Summary of a Workshop. Gastroenterology 2001;120:1828-1853.
    • (2001) Gastroenterology , vol.120 , pp. 1828-1853
    • Lok, A.S.1    Heattcote, E.J.2    Hoofnagle, J.H.3
  • 220
    • 70350037583 scopus 로고    scopus 로고
    • Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naive HBeAg-positive patients with chronic hepatitis B
    • Chang TT, Chao YC, Gorbakov VV, Han KH, Gish RG, de Man R, et al. Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naive HBeAg-positive patients with chronic hepatitis B. J Viral Hepat 2009;16:784-789.
    • (2009) J Viral Hepat , vol.16 , pp. 784-789
    • Chang, T.T.1    Chao, Y.C.2    Gorbakov, V.V.3    Han, K.H.4    Gish, R.G.5    de Man, R.6
  • 221
    • 85007414156 scopus 로고    scopus 로고
    • Tenofovir alafenamide demonstrates broad cross-genotype activity against wild-type HBV clinical isolates and maintains susceptibility to drug-resistant HBV isolates in vitro
    • Liu Y, Miller MD, Kitrinos KM. Tenofovir alafenamide demonstrates broad cross-genotype activity against wild-type HBV clinical isolates and maintains susceptibility to drug-resistant HBV isolates in vitro. Antiviral Res 2017;139:25-31.
    • (2017) Antiviral Res , vol.139 , pp. 25-31
    • Liu, Y.1    Miller, M.D.2    Kitrinos, K.M.3
  • 223
    • 66149115173 scopus 로고    scopus 로고
    • Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy
    • Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503-1514.
    • (2009) Hepatology , vol.49 , pp. 1503-1514
    • Tenney, D.J.1    Rose, R.E.2    Baldick, C.J.3    Pokornowski, K.A.4    Eggers, B.J.5    Fang, J.6
  • 224
    • 79959736811 scopus 로고    scopus 로고
    • Add-on adefovir is superior to a switch to entecavir as rescue therapy for Lamivudine-resistant chronic hepatitis B.[Erratum appears in Dig Dis Sci 2011 Aug;56(8):2509]
    • Chung GE, Kim W, Lee KL, Hwang SY, Lee JH, Kim HY, et al. Add-on adefovir is superior to a switch to entecavir as rescue therapy for Lamivudine-resistant chronic hepatitis B.[Erratum appears in Dig Dis Sci 2011 Aug;56(8):2509]. Dig Dis Sci 2011;56:2130-2136.
    • (2011) Dig Dis Sci , vol.56 , pp. 2130-2136
    • Chung, G.E.1    Kim, W.2    Lee, K.L.3    Hwang, S.Y.4    Lee, J.H.5    Kim, H.Y.6
  • 225
    • 84890310910 scopus 로고    scopus 로고
    • Comparison of the efficacy of Lamivudine plus adefovir versus entecavir in the treatment of Lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis
    • Huang ZB, Zhao SS, Huang Y, Dai XH, Zhou RR, Yi PP, et al. Comparison of the efficacy of Lamivudine plus adefovir versus entecavir in the treatment of Lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. Clin Ther 2013;35:1997-2006.
    • (2013) Clin Ther , vol.35 , pp. 1997-2006
    • Huang, Z.B.1    Zhao, S.S.2    Huang, Y.3    Dai, X.H.4    Zhou, R.R.5    Yi, P.P.6
  • 226
    • 77954914077 scopus 로고    scopus 로고
    • Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy
    • Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy. J Gastroenterol Hepatol 2010;25:1374-1380.
    • (2010) J Gastroenterol Hepatol , vol.25 , pp. 1374-1380
    • Kim, H.J.1    Park, J.H.2    Park, D.I.3    Cho, Y.K.4    Sohn, C.I.5    Jeon, W.K.6    Kim, B.I.7
  • 227
    • 84946173044 scopus 로고    scopus 로고
    • Efficacy of Tenofovir-based Rescue Therapy in Lamivudine-resistant Chronic Hepatitis B Patients With Failure of Lamivudine and Adefovir Combination
    • Park JH, Jung SW, Park NH, Park BR, Kim MH, Kim CJ, et al. Efficacy of Tenofovir-based Rescue Therapy in Lamivudine-resistant Chronic Hepatitis B Patients With Failure of Lamivudine and Adefovir Combination. Clin Ther 2015;37:1433-1442.
    • (2015) Clin Ther , vol.37 , pp. 1433-1442
    • Park, J.H.1    Jung, S.W.2    Park, N.H.3    Park, B.R.4    Kim, M.H.5    Kim, C.J.6
  • 228
    • 63049107827 scopus 로고    scopus 로고
    • Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?
    • Suzuki Y, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, et al. Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance? J Gastroenterol Hepatol 2009;24:429-435.
    • (2009) J Gastroenterol Hepatol , vol.24 , pp. 429-435
    • Suzuki, Y.1    Suzuki, F.2    Kawamura, Y.3    Yatsuji, H.4    Sezaki, H.5    Hosaka, T.6
  • 229
    • 84872159453 scopus 로고    scopus 로고
    • Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial
    • Yim HJ, Seo YS, Yoon EL, Kim CW, Lee CD, Park SH, et al. Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial. Liver Int 2013;33:244-254.
    • (2013) Liver Int , vol.33 , pp. 244-254
    • Yim, H.J.1    Seo, Y.S.2    Yoon, E.L.3    Kim, C.W.4    Lee, C.D.5    Park, S.H.6
  • 230
    • 25444459427 scopus 로고    scopus 로고
    • Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir
    • Sheldon J, Camino N, Rodes B, Bartholomeusz A, Kuiper M, Tacke F, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005;10:727-734.
    • (2005) Antivir Ther , vol.10 , pp. 727-734
    • Sheldon, J.1    Camino, N.2    Rodes, B.3    Bartholomeusz, A.4    Kuiper, M.5    Tacke, F.6
  • 231
    • 85000692609 scopus 로고    scopus 로고
    • Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study
    • Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW, et al. Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study. J Hepatol 2017;66:11-18.
    • (2017) J Hepatol , vol.66 , pp. 11-18
    • Fung, S.1    Kwan, P.2    Fabri, M.3    Horban, A.4    Pelemis, M.5    Hann, H.W.6
  • 232
    • 84896392012 scopus 로고    scopus 로고
    • Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients
    • Berg T, Zoulim F, Moeller B, Trinh H, Marcellin P, Chan S, et al. Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients. J Hepatol 2014;60:715-722.
    • (2014) J Hepatol , vol.60 , pp. 715-722
    • Berg, T.1    Zoulim, F.2    Moeller, B.3    Trinh, H.4    Marcellin, P.5    Chan, S.6
  • 233
    • 73449121925 scopus 로고    scopus 로고
    • Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues
    • van Bömmel F, de Man R, Wedemeyer H, Deterding K, Petersen J, Buggisch P, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010;51:73-80.
    • (2010) Hepatology , vol.51 , pp. 73-80
    • van Bömmel, F.1    de Man, R.2    Wedemeyer, H.3    Deterding, K.4    Petersen, J.5    Buggisch, P.6
  • 234
    • 84929606836 scopus 로고    scopus 로고
    • Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis
    • Jang JW, Choi JY, Kim YS, Woo HY, Choi SK, Lee CH, et al. Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis. Hepatology 2015;61:1809-1820.
    • (2015) Hepatology , vol.61 , pp. 1809-1820
    • Jang, J.W.1    Choi, J.Y.2    Kim, Y.S.3    Woo, H.Y.4    Choi, S.K.5    Lee, C.H.6
  • 235
    • 84863987122 scopus 로고    scopus 로고
    • Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy
    • Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol 2012;57:442-450.
    • (2012) J Hepatol , vol.57 , pp. 442-450
    • Peng, C.Y.1    Chien, R.N.2    Liaw, Y.F.3
  • 236
    • 75349107764 scopus 로고    scopus 로고
    • Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis
    • Shim JH, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, Suh DJ. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010;52:176-182.
    • (2010) J Hepatol , vol.52 , pp. 176-182
    • Shim, J.H.1    Lee, H.C.2    Kim, K.M.3    Lim, Y.S.4    Chung, Y.H.5    Lee, Y.S.6    Suh, D.J.7
  • 237
    • 84905593851 scopus 로고    scopus 로고
    • Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis
    • Kim SS, Hwang JC, Lim SG, Ahn SJ, Cheong JY, Cho SW. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis. Am J Gastroenterol 2014;109:1223-1233.
    • (2014) Am J Gastroenterol , vol.109 , pp. 1223-1233
    • Kim, S.S.1    Hwang, J.C.2    Lim, S.G.3    Ahn, S.J.4    Cheong, J.Y.5    Cho, S.W.6
  • 238
    • 84922226942 scopus 로고    scopus 로고
    • Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir
    • Papatheodoridis GV, Dalekos GN, Yurdaydin C, Buti M, Goulis J, Arends P, et al. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. J Hepatol 2015;62:363-370.
    • (2015) J Hepatol , vol.62 , pp. 363-370
    • Papatheodoridis, G.V.1    Dalekos, G.N.2    Yurdaydin, C.3    Buti, M.4    Goulis, J.5    Arends, P.6
  • 239
    • 84879241608 scopus 로고    scopus 로고
    • Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B
    • Singal AK, Salameh H, Kuo YF, Fontana RJ. Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. Aliment Pharmacol Ther 2013;38:98-106.
    • (2013) Aliment Pharmacol Ther , vol.38 , pp. 98-106
    • Singal, A.K.1    Salameh, H.2    Kuo, Y.F.3    Fontana, R.J.4
  • 240
    • 68149178482 scopus 로고    scopus 로고
    • Antiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infection
    • Iacobellis A, Andriulli A. Antiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infection. Expert Opin Pharmacother 2009;10:1929-1938.
    • (2009) Expert Opin Pharmacother , vol.10 , pp. 1929-1938
    • Iacobellis, A.1    Andriulli, A.2
  • 241
    • 84986275159 scopus 로고    scopus 로고
    • Entecavir for Patients with Hepatitis B Decompensated Cirrhosis in China: a meta-analysis
    • Wang FY, Li B, Li Y, Liu H, Qu WD, Xu HW, et al. Entecavir for Patients with Hepatitis B Decompensated Cirrhosis in China: a meta-analysis. Sci Rep 2016;6:32722.
    • (2016) Sci Rep , vol.6 , pp. 32722
    • Wang, F.Y.1    Li, B.2    Li, Y.3    Liu, H.4    Qu, W.D.5    Xu, H.W.6
  • 242
    • 84922664888 scopus 로고    scopus 로고
    • The efficacy and safety of entecavir in patients with chronic hepatitis B- associated liver failure: a meta-analysis
    • Zhang X, Liu L, Zhang M, Gao S, Du Y, An Y, Chen S. The efficacy and safety of entecavir in patients with chronic hepatitis B- associated liver failure: a meta-analysis. Ann Hepatol 2015;14:150-160.
    • (2015) Ann Hepatol , vol.14 , pp. 150-160
    • Zhang, X.1    Liu, L.2    Zhang, M.3    Gao, S.4    Du, Y.5    An, Y.6    Chen, S.7
  • 243
    • 84874904588 scopus 로고    scopus 로고
    • Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice
    • Miquel M, Nunez O, Trapero-Marugan M, Diaz-Sanchez A, Jimenez M, Arenas J, Canos AP. Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice. Ann Hepatol 2013;12:205-212.
    • (2013) Ann Hepatol , vol.12 , pp. 205-212
    • Miquel, M.1    Nunez, O.2    Trapero-Marugan, M.3    Diaz-Sanchez, A.4    Jimenez, M.5    Arenas, J.6    Canos, A.P.7
  • 244
    • 84886882616 scopus 로고    scopus 로고
    • Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: meta-analysis
    • Ye XG, Su QM. Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: meta-analysis. World J Gastroenterol 2013;19:6665-6678.
    • (2013) World J Gastroenterol , vol.19 , pp. 6665-6678
    • Ye, X.G.1    Su, Q.M.2
  • 246
    • 84964328586 scopus 로고    scopus 로고
    • Telbivudine versus lamivudine and entecavir for treatment-naive decompensated hepatitis B virus-related cirrhosis
    • Yue-Meng W, Li YH, Wu HM, Yang J, Xu Y, Yang LH, Yang JH. Telbivudine versus lamivudine and entecavir for treatment-naive decompensated hepatitis B virus-related cirrhosis. Clin Exp Med 2017;17:233-241.
    • (2017) Clin Exp Med , vol.17 , pp. 233-241
    • Yue-Meng, W.1    Li, Y.H.2    Wu, H.M.3    Yang, J.4    Xu, Y.5    Yang, L.H.6    Yang, J.H.7
  • 247
    • 84857368529 scopus 로고    scopus 로고
    • Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis
    • Singal AK, Fontana RJ. Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis. Aliment Pharmacol Ther 2012;35:674-689.
    • (2012) Aliment Pharmacol Ther , vol.35 , pp. 674-689
    • Singal, A.K.1    Fontana, R.J.2
  • 248
    • 78751491184 scopus 로고    scopus 로고
    • Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease
    • Liaw YF, Sheen IS, Lee CM, Akarca US, Papatheodoridis GV, Suet-Hing Wong F, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011;53:62-72.
    • (2011) Hepatology , vol.53 , pp. 62-72
    • Liaw, Y.F.1    Sheen, I.S.2    Lee, C.M.3    Akarca, U.S.4    Papatheodoridis, G.V.5    Suet-Hing Wong, F.6
  • 249
    • 85017162704 scopus 로고    scopus 로고
    • Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis
    • Lee SK, Song MJ, Kim SH, Lee BS, Lee TH, Kang YW, et al. Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis. World J Gastroenterol 2017;23:2396-2403.
    • (2017) World J Gastroenterol , vol.23 , pp. 2396-2403
    • Lee, S.K.1    Song, M.J.2    Kim, S.H.3    Lee, B.S.4    Lee, T.H.5    Kang, Y.W.6
  • 250
    • 85031292742 scopus 로고    scopus 로고
    • Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis
    • Park J, Jung KS, Lee HW, Kim BK, Kim SU, Kim DY, et al. Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis. Gut Liver 2017;11:828-834.
    • (2017) Gut Liver , vol.11 , pp. 828-834
    • Park, J.1    Jung, K.S.2    Lee, H.W.3    Kim, B.K.4    Kim, S.U.5    Kim, D.Y.6
  • 251
    • 73149085984 scopus 로고    scopus 로고
    • Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function
    • Lange CM, Bojunga J, Hofmann WP, Wunder K, Mihm U, Zeuzem S, Sarrazin C. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009;50:2001-2006.
    • (2009) Hepatology , vol.50 , pp. 2001-2006
    • Lange, C.M.1    Bojunga, J.2    Hofmann, W.P.3    Wunder, K.4    Mihm, U.5    Zeuzem, S.6    Sarrazin, C.7
  • 252
    • 84860389498 scopus 로고    scopus 로고
    • Individualizing hepatitis B infection prophylaxis in liver transplant recipients
    • Fox AN, Terrault NA. Individualizing hepatitis B infection prophylaxis in liver transplant recipients. J Hepatol 2011;55:507-509.
    • (2011) J Hepatol , vol.55 , pp. 507-509
    • Fox, A.N.1    Terrault, N.A.2
  • 253
    • 85017622308 scopus 로고    scopus 로고
    • Short Course of Post-Operative Hepatitis B Immunoglobulin plus Antivirals Prevents Reinfection of Liver Transplant Recipients
    • Radhakrishnan K, Chi A, Quan D, Roberts J, Terrault N. Short Course of Post-Operative Hepatitis B Immunoglobulin plus Antivirals Prevents Reinfection of Liver Transplant Recipients. Transplantation 2017;101:2079-2082.
    • (2017) Transplantation , vol.101 , pp. 2079-2082
    • Radhakrishnan, K.1    Chi, A.2    Quan, D.3    Roberts, J.4    Terrault, N.5
  • 254
    • 84987689958 scopus 로고    scopus 로고
    • Randomized Trial of Emtricitabine/Tenofovir DF Plus/Minus HBIG Withdrawal in Prevention of Chronic Hepatitis B Recurrence Post-Liver Transplantation: 48 Week Results
    • Teperman L, Spivey J, Poordad F, Schiano T, Bzowej N, Martin P, et al. Randomized Trial of Emtricitabine/Tenofovir DF Plus/Minus HBIG Withdrawal in Prevention of Chronic Hepatitis B Recurrence Post-Liver Transplantation: 48 Week Results. Am J Transplant 2011;11(Suppl 2):48.
    • (2011) Am J Transplant , vol.11 , pp. 48
    • Teperman, L.1    Spivey, J.2    Poordad, F.3    Schiano, T.4    Bzowej, N.5    Martin, P.6
  • 255
    • 85026544921 scopus 로고    scopus 로고
    • Long Term Outcomes of Entecavir Monotherapy for Chronic Hepatitis B after Liver Transplantation: Results up to 8 years
    • Fung J, Wong T, Chok K, Chan A, Cheung TT, Dai J, et al. Long Term Outcomes of Entecavir Monotherapy for Chronic Hepatitis B after Liver Transplantation: Results up to 8 years. Hepatology 2017;66:1036-1044.
    • (2017) Hepatology , vol.66 , pp. 1036-1044
    • Fung, J.1    Wong, T.2    Chok, K.3    Chan, A.4    Cheung, T.T.5    Dai, J.6
  • 256
    • 77951219796 scopus 로고    scopus 로고
    • Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients
    • Coffin CS, Stock PG, Dove LM, Berg CL, Nissen NN, Curry MP, et al. Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients. Am J Transplant 2010;10:1268-1275.
    • (2010) Am J Transplant , vol.10 , pp. 1268-1275
    • Coffin, C.S.1    Stock, P.G.2    Dove, L.M.3    Berg, C.L.4    Nissen, N.N.5    Curry, M.P.6
  • 257
    • 84961944312 scopus 로고    scopus 로고
    • Early Introduction of Subcutaneous Hepatitis B Immunoglobulin Following Liver Transplantation for Hepatitis B Virus Infection: A Prospective, Multicenter Study
    • De Simone P, Romagnoli R, Tandoi F, Carrai P, Ercolani G, Peri E, Zamboni F, et al. Early Introduction of Subcutaneous Hepatitis B Immunoglobulin Following Liver Transplantation for Hepatitis B Virus Infection: A Prospective, Multicenter Study. Transplantation 2016;100:1507-1512.
    • (2016) Transplantation , vol.100 , pp. 1507-1512
    • De Simone, P.1    Romagnoli, R.2    Tandoi, F.3    Carrai, P.4    Ercolani, G.5    Peri, E.6    Zamboni, F.7
  • 258
    • 0032722346 scopus 로고    scopus 로고
    • Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation
    • Yao FY, Osorio RW, Roberts JP, Poordad FF, Briceno MN, Garcia-Kennedy R, Gish RR. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg 1999;5:491-496.
    • (1999) Liver Transpl Surg , vol.5 , pp. 491-496
    • Yao, F.Y.1    Osorio, R.W.2    Roberts, J.P.3    Poordad, F.F.4    Briceno, M.N.5    Garcia-Kennedy, R.6    Gish, R.R.7
  • 259
    • 75349089062 scopus 로고    scopus 로고
    • Liver grafts from anti-hepatitis B core positive donors: a systematic review
    • Cholongitas E, Papatheodoridis GV, Burroughs AK. Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol 2010;52:272-279.
    • (2010) J Hepatol , vol.52 , pp. 272-279
    • Cholongitas, E.1    Papatheodoridis, G.V.2    Burroughs, A.K.3
  • 260
    • 67649209485 scopus 로고    scopus 로고
    • Hepatitis B virus prevention strategies for antibody to hepatitis B core antigen-positive liver donation: a survey of North American, European, and Asian-Pacific transplant programs
    • Perrillo R. Hepatitis B virus prevention strategies for antibody to hepatitis B core antigen-positive liver donation: a survey of North American, European, and Asian-Pacific transplant programs. Liver Transpl 2009;15:223-232.
    • (2009) Liver Transpl , vol.15 , pp. 223-232
    • Perrillo, R.1
  • 262
    • 84973473774 scopus 로고    scopus 로고
    • Pretransplant Hepatitis B Viral Infection Increases Risk of Death After Kidney Transplantation: A Multicenter Cohort Study in Korea
    • Lee J, Cho JH, Lee JS, Ahn DW, Kim CD, Ahn C, et al. Pretransplant Hepatitis B Viral Infection Increases Risk of Death After Kidney Transplantation: A Multicenter Cohort Study in Korea. Medicine (Baltimore) 2016;95:e3671.
    • (2016) Medicine (Baltimore) , vol.95
    • Lee, J.1    Cho, J.H.2    Lee, J.S.3    Ahn, D.W.4    Kim, C.D.5    Ahn, C.6
  • 263
    • 33644819694 scopus 로고    scopus 로고
    • HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies
    • Fabrizi F, Martin P, Dixit V, Kanwal F, Dulai G. HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant 2005;5:2913-2921.
    • (2005) Am J Transplant , vol.5 , pp. 2913-2921
    • Fabrizi, F.1    Martin, P.2    Dixit, V.3    Kanwal, F.4    Dulai, G.5
  • 264
    • 0036829841 scopus 로고    scopus 로고
    • Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients
    • Chan TM, Fang GX, Tang CS, Cheng IK, Lai KN, Ho SK. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology 2002;36:1246-1252.
    • (2002) Hepatology , vol.36 , pp. 1246-1252
    • Chan, T.M.1    Fang, G.X.2    Tang, C.S.3    Cheng, I.K.4    Lai, K.N.5    Ho, S.K.6
  • 265
    • 77955424877 scopus 로고    scopus 로고
    • Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments
    • Yap DY, Tang CS, Yung S, Choy BY, Yuen MF, Chan TM. Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments. Transplantation 2010;90:325-330.
    • (2010) Transplantation , vol.90 , pp. 325-330
    • Yap, D.Y.1    Tang, C.S.2    Yung, S.3    Choy, B.Y.4    Yuen, M.F.5    Chan, T.M.6
  • 266
    • 0028799577 scopus 로고
    • The risk of transmission of hepatitis B from HBsAg(−), HBcAb(+), HBIgM(−) organ donors
    • Wachs ME, Amend WJ, Ascher NL, Bretan PN, Emond J, Lake JR, et al. The risk of transmission of hepatitis B from HBsAg(−), HBcAb(+), HBIgM(−) organ donors. Transplantation 1995;59:230-234.
    • (1995) Transplantation , vol.59 , pp. 230-234
    • Wachs, M.E.1    Amend, W.J.2    Ascher, N.L.3    Bretan, P.N.4    Emond, J.5    Lake, J.R.6
  • 267
    • 84867628764 scopus 로고    scopus 로고
    • Renal grafts from anti-hepatitis B core-positive donors: a quantitative review of the literature
    • Mahboobi N, Tabatabaei SV, Blum HE, Alavian SM. Renal grafts from anti-hepatitis B core-positive donors: a quantitative review of the literature. Transpl Infect Dis 2012;14:445-451.
    • (2012) Transpl Infect Dis , vol.14 , pp. 445-451
    • Mahboobi, N.1    Tabatabaei, S.V.2    Blum, H.E.3    Alavian, S.M.4
  • 268
    • 0030799619 scopus 로고    scopus 로고
    • Risks of transplanting kidneys from hepatitis B surface antigen-negative, hepatitis B core antibody-positive donors
    • Satterthwaite R, Ozgu I, Shidban H, Aswad S, Sunga V, Zapanta R, Jr., et al. Risks of transplanting kidneys from hepatitis B surface antigen-negative, hepatitis B core antibody-positive donors. Transplantation 1997;64:432-435.
    • (1997) Transplantation , vol.64 , pp. 432-435
    • Satterthwaite, R.1    Ozgu, I.2    Shidban, H.3    Aswad, S.4    Sunga, V.5    Zapanta, R.6
  • 270
    • 85060838557 scopus 로고    scopus 로고
    • New pediatric percentiles of liver enzyme serum levels (ALT, AST, GGT): Effects of age, sex, BMI and pubertal stage
    • Sep 19., [Epub ahead of print]
    • Bussler S, Vogel M, Pietzner D, Harms K, Buzek T, Penke M, et al. New pediatric percentiles of liver enzyme serum levels (ALT, AST, GGT): Effects of age, sex, BMI and pubertal stage. Hepatology 2017 Sep 19. doi: 10.1002/hep.29542. [Epub ahead of print]
    • (2017) Hepatology
    • Bussler, S.1    Vogel, M.2    Pietzner, D.3    Harms, K.4    Buzek, T.5    Penke, M.6
  • 272
    • 77949816251 scopus 로고    scopus 로고
    • SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease
    • 1364.e1-2
    • Schwimmer JB, Dunn W, Norman GJ, Pardee PE, Middleton MS, Kerkar N, Sirlin CB. SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease. Gastroenterology 2010;138:1357-1364, 1364.e1-2.
    • (2010) Gastroenterology , vol.138 , pp. 1357-1364
    • Schwimmer, J.B.1    Dunn, W.2    Norman, G.J.3    Pardee, P.E.4    Middleton, M.S.5    Kerkar, N.6    Sirlin, C.B.7
  • 273
    • 67651049819 scopus 로고    scopus 로고
    • Age- and sex-related reference ranges of alanine aminotransferase levels in children: European paediatric HCV network
    • England K, Thorne C, Pembrey L, Tovo PA, Newell ML. Age- and sex-related reference ranges of alanine aminotransferase levels in children: European paediatric HCV network. J Pediatr Gastroenterol Nutr 2009;49:71-77.
    • (2009) J Pediatr Gastroenterol Nutr , vol.49 , pp. 71-77
    • England, K.1    Thorne, C.2    Pembrey, L.3    Tovo, P.A.4    Newell, M.L.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.